[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 662
1. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Radiographic objective responses (partial responses) were observed in two patients with astrocytoma grade III and in one patient each with neuroblastoma and pleomorphic rhabdomyosarcoma, respectively.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


2. Söling A, Sackewitz M, Volkmar M, Schaarschmidt D, Jacob R, Holzhausen HJ, Rainov NG: Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. Clin Cancer Res; 2005 Jan 1;11(1):249-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma.
  • PURPOSE: The identification of new molecular markers in astrocytic tumors may help to understand the biology of these tumors in more detail.
  • Informative tumor markers may represent prognostic factors for response to therapy and outcome as well as potential targets for novel anticancer therapies.
  • EXPERIMENTAL DESIGN: Tumor-associated antigens were identified by immunoscreening of a human glioma cDNA expression library with allogeneic sera from patients with diffuse astrocytoma (WHO grades 2-4).
  • The expression of one of the identified antigens, the replication licensing factor minichromosome maintenance protein 3 (MCM3), was analyzed by immunohistochemistry in 142 primary and 27 recurrent astrocytomas (WHO grades 2-4).
  • RESULTS: MCM3 is overexpressed in human astrocytic tumors and elicits a cancer-restricted humoral immune response in 9.3% (9 of 97) of patients with brain tumors (n = 95) and brain metastases (n = 2) but not in healthy controls.
  • Expression of MCM3 in diffuse astrocytoma is significantly associated with age (P < 0.001), histologic grade (P < 0.001), time to recurrence (P = 0.01), and expression of the proliferation marker Ki-67 (P < 0.001) but not with sex (P = 0.800).
  • Univariate and multivariate Cox regression analysis confirmed MCM3 expression as an independent predictor of poor outcome in astrocytoma patients (P < 0.001 for both).
  • [MeSH-major] Astrocytoma / immunology. Astrocytoma / mortality. Brain Neoplasms / immunology. Brain Neoplasms / mortality. DNA-Binding Proteins / physiology. Gene Expression Regulation, Neoplastic. Nuclear Proteins / physiology. Transcription Factors / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytes / metabolism. Cell Cycle Proteins. DNA, Complementary / metabolism. Disease-Free Survival. Escherichia coli / metabolism. Female. Gene Library. Glioma / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Minichromosome Maintenance Complex Component 3. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671553.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / MCM3 protein, human; 0 / Nuclear Proteins; 0 / Transcription Factors; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 3
  •  go-up   go-down


3. Gu X, Jones L, Lowery-Norberg M, Fowler M: Expression of eukaryotic initiation factor 4E in astrocytic tumors. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):178-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of eukaryotic initiation factor 4E in astrocytic tumors.
  • In this immunohistochemical study, eIF4E protein expression was investigated in human brain tissue from patients without central nervous system diseases and brain biopsy tissues from patients with anaplastic astrocytoma and glioblastoma multiforme.
  • In anaplastic astrocytoma and glioblastoma multiforme, there was diffuse uniform expression of eIF4E immunoreactivity in malignant astrocytes.
  • This study provides evidence that eIF4E is upregulated in high-grade astrocytic tumors.
  • As in other malignancies, a high level of eIF4E may play an important role in the neoplastic transformation, angiogenesis, and tumor growth in astrocytic tumors.
  • Because eIF4E is crucial in regulation of tumor growth, eIF4E could be a potential target for inhibitors as an adjuvant therapy for brain tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894932.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-4E
  •  go-up   go-down


Advertisement
4. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res; 2006;16(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
  • In the last years results of preclinical and clinical studies have suggested that LMWH may be able to inhibit cell growth, cell invasion, and angiogenesis, which are key mechanisms involved in tumor progression, possibly influencing favorable clinical outcome in at least a proportion of cancer patients.
  • In this work we investigated the effect of LMWH (enoxaparin) on cell growth and cell invasion in primary cell cultures obtained from high-grade glioma specimens: 5 anaplastic astrocytoma (AA) and 13 glioblastoma multiforme (GBM).
  • A significant decrease in tumor cell growth was observed after treatment with 10 U/ml (-21%; p = 0.001) and 100 U/ml (-26%; p < 0.001); tumor cells from AA (grade III;.
  • WHO) were more affected by LMWH treatment compared to cell lines from GBM (grade IV; WHO).
  • In conclusion, our results confirm the antineoplastic effect of LMWH, suggesting a potential direct role on tumor cell growth in high grade gliomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Receptor, PAR-1 / biosynthesis. Receptor, PAR-1 / drug effects. Receptor, PAR-1 / genetics. Sensitivity and Specificity. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294805.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin; 0 / Receptor, PAR-1
  •  go-up   go-down


5. Zhang L, Yamane T, Satoh E, Amagasaki K, Kawataki T, Asahara T, Furuya K, Nukui H, Naganuma H: Establishment and partial characterization of five malignant glioma cell lines. Neuropathology; 2005 Jun;25(2):136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and partial characterization of five malignant glioma cell lines.
  • Five malignant glioma cell lines (YMG1, 2, 3, 4, and 5) were established from surgical specimens obtained from patients with glioblastoma or anaplastic astrocytoma, and these lines were partially characterized.
  • YMG5 revealed weak expression of p53 protein, suggesting wild-type p53, and loss of p16 and p15 expression.
  • Immunohistochemical studies revealed that the patterns of p53 and EGFR expressions in the original tumor tissues were mostly correlated with those in the malignant glioma cell lines.
  • These results suggest that the characteristics of p53 and EGFR expression in the malignant glioma cell lines were passed over from the original tumor tissues.
  • These newly established malignant glioma cell lines can be used for further analysis of the mechanisms of tumor growth and progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Line, Tumor. Gene Expression. Glioma / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Cycle Proteins / biosynthesis. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p15. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cyclin-Dependent Kinases / biosynthesis. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Proto-Oncogene Proteins / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. S100 Proteins / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875906.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Glial Fibrillary Acidic Protein; 0 / Proto-Oncogene Proteins; 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


6. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A: Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery; 2009 Sep;65(3):463-9; discussion 469-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Balancing the benefits of extensive tumor resection with the consequence of potential postoperative deficits remains a challenge in malignant astrocytoma surgery.


7. Hata N, Yoshimoto K, Yokoyama N, Mizoguchi M, Shono T, Guan Y, Tahira T, Kukita Y, Higasa K, Nagata S, Iwaki T, Sasaki T, Hayashi K: Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis. Clin Chem; 2006 Mar;52(3):370-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Detection of loss of heterozygosity (LOH) in clinical tissue samples is frequently difficult because samples are usually contaminated with noncancerous cells or because tumor cells in single tissues have genetic heterogeneity, and the precision of available techniques is insufficient for reliable analysis in such materials.
  • Anaplastic astrocytomas exhibited both 10p and 10q LOH, whereas diffuse astrocytomas frequently (63% of the cases) exhibited loss of 10p alone.
  • CONCLUSIONS: The present method is effective for precise mapping of LOH region in surgically obtained tumor tissues and could be applicable to the genetic diagnosis of cancers other than gliomas.
  • [MeSH-minor] Alleles. Astrocytoma / genetics. Humans. Polymorphism, Single Nucleotide


8. Uro-Coste E, Ssi-Yan-Kai G, Guilbeau-Frugier C, Boetto S, Bertozzi AI, Sevely A, Lolmede K, Delisle MB: Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation. J Neurooncol; 2010 May;98(1):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation.
  • Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are rare intracranial tumors that mostly occur in the first 2 years of life and involve superficial cerebral cortex.
  • We report an original observation of a desmoplastic infantile astrocytoma in a 5-year-old boy with multiple localizations on initial presentation, including the unusual subtentorial region.
  • Magnetic resonance imaging showed a temporal tumor with prepontine and interpeduncular extension, and two other distinct localizations in cisterna magna and left cerebellar hemisphere.
  • The surgical samples, corresponding exclusively to subtentorial lesions, were devoid of anaplastic features; the temporal lesion was untouched because of the interpeduncular extension.
  • When the tumor is large, multilobular involvement is common, but multiple location of DIG is, on the contrary, very rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology


9. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • One year later, the anaplastic astrocytoma was found to have transformed into a glioblastoma multiforme.
  • Fluorescence in situ hybridization analysis and immunohistochemical examinations detected deletions of the lp36 and 19q13 loci, and nuclear accumulation of TP53 protein in the anaplastic oligodendroglioma but not in the glioblastoma multiforme.
  • These findings suggest that central neurocytoma or progenitor cells have the potential for oligodendrocytic and astrocytic transformation with different genetic aberrations.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


10. Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, Itoh K, Yamada A: Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci; 2008 Aug;99(8):1656-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we examined the expression of the EphB6 variant (EphB6v) in a panel of brain tumor cell lines and glioblastoma tissues and we found that EphB6v was preferentially expressed in malignant brain tumors, such as glioblastomas and anaplastic astrocytomas.
  • [MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Case-Control Studies. Cell Line, Tumor. Gene Expression. Glioblastoma / metabolism. HLA-A Antigens. HLA-A2 Antigen. Hepatocytes. Humans

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754880.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; EC 2.7.1.- / EPHB6 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


11. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K, Meyer HE, Reifenberger G: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol; 2010 May;20(3):539-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of microRNAs involved in the malignant progression of gliomas.
  • Diffuse astrocytoma of World Health Organization (WHO) grade II has an inherent tendency to spontaneously progress to anaplastic astrocytoma WHO grade III or secondary glioblastoma WHO grade IV.
  • We explored the role of microRNAs (miRNAs) in glioma progression by investigating the expression profiles of 157 miRNAs in four patients with primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas.
  • Validation experiments on independent series of primary low-grade and secondary high-grade astrocytomas confirmed miR-17 and miR-184 as promising candidates, which were selected for functional analyses.
  • [MeSH-minor] Cell Dedifferentiation / physiology. Cell Line, Tumor. Disease Progression. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775293.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


12. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • This promising activity warrants further investigation of this combination in larger phase II or III studies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


13. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Quant EC, Drappatz J, Wen PY, Norden AD: Recurrent high-grade glioma. Curr Treat Options Neurol; 2010 Jul;12(4):321-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent high-grade glioma.
  • OPINION STATEMENT: Opinions vary on the best treatment options for recurrent high-grade glioma.
  • Age, performance status, histology, tumor size and location, O6-methylguanine-DNA methyltransferase (MGMT) methylation status for glioblastoma, 1p/19q status for oligodendroglial tumors, and the number and types of prior therapies are important considerations.
  • Enrollment in a clinical trial is the optimal choice for most patients with recurrent high-grade glioma after failure of radiation therapy and temozolomide.
  • Involved-field external beam radiation should be considered for patients with anaplastic gliomas who have not received radiation.
  • For patients with anaplastic astrocytoma who progress after radiotherapy, temozolomide may be used.
  • For patients with anaplastic oligodendroglioma who progress after radiotherapy, PCV chemotherapy and temozolomide are options.
  • In the past, carmustine was commonly used to treat recurrent high-grade glioma, but the utility of carmustine in the modern era is unknown because most studies were performed prior to the widespread use of temozolomide.
  • High-precision re-irradiation such as stereotactic radiosurgery is another option in high-grade glioma, especially for patients with poor bone marrow reserve or inability to tolerate chemotherapy, but there is a paucity of studies with adequate controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 10;23 (23 ):5294-304 [15998902.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):550-5 [19332770.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Surg Neurol. 2008 May;69(5):506-9; discussion 509 [18262245.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] BMC Cancer. 2007 Aug 30;7:167 [17760992.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):167-73 [8145061.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2905-8 [19451418.001]
  • [Cites] Ther Clin Risk Manag. 2007 Oct;3(5):707-15 [18472995.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Mol Cells. 2009 Jul 31;28(1):7-12 [19655094.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):81-3 [16944309.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55 [19543728.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 [18037587.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):300-5 [18525311.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Lancet Neurol. 2008 Dec;7(12):1152-60 [19007739.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 [18272557.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1141-71, x [17964029.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20842591.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, Carter NP, Collins VP: Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene; 2006 Feb 23;25(8):1261-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH.
  • Deletions of chromosome 6 are a common abnormality in diverse human malignancies including astrocytic tumours, suggesting the presence of tumour suppressor genes (TSG).
  • A total of 104 adult astrocytic tumours (10 diffuse astrocytomas, 30 anaplastic astrocytomas (AA), 64 glioblastomas (GB)) were analysed using this array.
  • [MeSH-major] Astrocytoma / genetics. Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Glioblastoma / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Artificial, Bacterial. DNA, Neoplasm / analysis. Gene Dosage. Humans. Microsatellite Repeats. Telomere / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Oncogene (2006) 25, 1261-1271. doi:10.1038/sj.onc.1209156; published online 3 October 2005.
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):435-42; discussion 432-3 [10416984.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):543-9 [10682663.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):302-5 [10888878.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Dec;59(12):1087-93 [11138928.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):942-3 [11237015.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):980-8 [11314033.001]
  • [Cites] Trends Genet. 2001 Jun;17(6):339-45 [11377796.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Jpn J Cancer Res. 2002 Feb;93(2):167-77 [11856480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4233-8 [11917126.001]
  • [Cites] BMC Genet. 2002 Oct 15;3:20 [12381271.001]
  • [Cites] J Mol Biol. 2003 Feb 7;326(1):11-9 [12547187.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):361-74 [12619160.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61 [12719539.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):421-6 [12800155.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Sep;38(1):40-52 [12874785.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):805-11 [14574404.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1261-70 [14628292.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51901-10 [14532270.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):133-42 [14964309.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):299-303 [14981516.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):32-7 [15034865.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1176-87 [15140828.001]
  • [Cites] Hum Mutat. 2004 Jul;24(1):76-85 [15221791.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):495-500 [15287941.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] Biochem J. 2004 Oct 15;383(Pt 2):319-25 [15170388.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):931-45 [15496913.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):405-11 [3335011.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1431-5 [7882347.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1395-8 [7478562.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1230-3 [7577473.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] J Neurosci. 1996 Dec 15;16(24):7941-9 [8987822.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):181-93 [15770670.001]
  • (PMID = 16205629.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2760128; NLM/ UKMS2686
  •  go-up   go-down


16. Shibui S: [Resent advances in chemotherapy for malignant brain tumors]. Gan To Kagaku Ryoho; 2005 Apr;32(4):442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resent advances in chemotherapy for malignant brain tumors].
  • Most malignant brain tumors are resistant to the chemotherapeutic agents because of the existence of several mechanisms or substances such as the blood-brain barrier, genes and proteins.
  • Especially recent advances in the field of molecular biology have contributed to examination of the chemosensitivities of tumor cells.
  • Loss of chromosome 1 p and 19 q is considered to be closely related to chemosensitivity in anaplastic oligodendrogliomas.
  • This is one of the breakthroughs in the field of chemotherapy for malignant brain tumors.
  • Multi-institutional randomized controlled study by JCOG Brain Tumor Study Group is the first trial for the treatment of malignant astrocytomas under well-established quality control and quality assurance systems.
  • It can be a model of clinical trials for malignant brain tumors in Japan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Clinical Trials, Phase II as Topic. Drug Resistance, Neoplasm. Humans. Nimustine / administration & dosage. Nitrosourea Compounds / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Procarbazine / administration & dosage. Quality Control. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853207.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 0S726V972K / Nimustine; 35S93Y190K / Procarbazine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Number-of-references] 27
  •  go-up   go-down


17. Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S, Basu S: Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. Neurol India; 2008 Oct-Dec;56(4):456-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas.
  • AIMS: The involvement of various growth factors, growth factor receptors and proliferative markers in the molecular pathogenesis of astrocytic neoplasms are being studied extensively.
  • Since EGFR and proliferating cell nuclear antigen (PCNA) are involved in mitogenic signal transduction and cellular proliferation pathway, we have studied the correlation between the expression of EGFR and PCNA labeling index in astrocytic tumors.
  • MATERIALS AND METHODS: We investigated the immunohistochemical expression of EGFR and PCNA using the appropriate monoclonal antibodies in 40 cases of astrocytic tumors of which 21 cases were glioblastoma, eight cases were Grade III or anaplastic astrocytomas and six cases were Grade II or diffuse astrocytomas and five cases were Grade I or pilocytic astrocytomas.
  • RESULTS: Both the EGFR expression and PCNA labeling index increase with increasing grades of astrocytomas with a significantly high percentage of cells showing positive staining for both EGFR and PCNA in GBM and Grade III astrocytomas compared to Grade II astrocytomas.
  • The expression levels of both EGFR and PCNA were low in Grade I or pilocytic astrocytomas.
  • CONCLUSIONS: A significant correlation was found between EGFR overexpression and PCNA labeling index in Grade III and Grade II astrocytomas and glioblastoma.
  • These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism


18. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C: Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci; 2008 Feb;15(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
  • Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma.
  • We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant / methods. Dendritic Cells / immunology. Immunotherapy, Active / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083572.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Cancer Vaccines; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


19. Maes L, Van Neste L, Van Damme K, Kalala JP, De Ridder L, Bekaert S, Cornelissen M: Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep; 2007 Dec;18(6):1571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Telomerase activity was detected in 3 of 35 (8.6%) screened meningiomas (1 benign, 1 atypical and 1 malignant meningioma).
  • For gliomas, no active telomerase was detected in 2 low-grade astrocytomas, whereas three of the four screened glioblastomas were positive for telomerase activity.
  • The only hTERT protein positive astrocytoma had a mean labelling index of 9.0%.
  • The two low-grade astrocytomas had a telomere length of 14.310 and 9.236 kb.
  • The anaplastic astrocytoma had a telomere length of 4.903 kb and the glioblastomas 5.767 kb (SD=2.042).
  • These results indicate that telomere shortening may be a critical step in pathogenesis of atypical and malignant meningiomas and gliomas.
  • [MeSH-minor] Astrocytoma / enzymology. Astrocytoma / genetics. Astrocytoma / pathology. Biopsy. Glioblastoma / enzymology. Glioblastoma / genetics. Glioblastoma / pathology. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982646.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


20. Debono B, Derrey S, Rabehenoina C, Proust F, Freger P, Laquerrière A: Primary diffuse multinodular leptomeningeal gliomatosis: case report and review of the literature. Surg Neurol; 2006 Mar;65(3):273-82; discussion 282
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary diffuse leptomeningeal gliomatosis is an exceptional neoplasm, and only 30 cases have been reported in the literature.
  • Histological examination revealed an anaplastic astrocytoma.
  • RESULTS: Complete neuraxis postmortem examination revealed no intraparenchymatous glioma and was conclusive for the diagnosis of primary leptomeningeal gliomatosis (astrocytic, World Health Organization grade III), with a multinodular pattern in the spinal cord, the brainstem, and the brain base with diffuse extension into the cerebellar subarachnoid spaces.
  • [MeSH-major] Astrocytoma / surgery. Meningeal Neoplasms / surgery. Neoplasms, Neuroepithelial / surgery. Peripheral Nervous System Neoplasms / surgery. Spinal Nerve Roots / surgery
  • [MeSH-minor] Brain / pathology. Cerebellum / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Intracranial Pressure / physiology. Male. Meninges / pathology. Middle Aged. Neoplasm Invasiveness / pathology. Neurologic Examination. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488248.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


21. Miyata S, Gomi A, Yamaguchi T, Tanaka Y, Watanabe E, Tanaka A: Case of unclassified, radiosensitive, malignant neuroepithelial tumor in the temporal lobe of a child. Brain Tumor Pathol; 2010 Apr;27(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of unclassified, radiosensitive, malignant neuroepithelial tumor in the temporal lobe of a child.
  • A case of unclassified, pediatric cerebral neuroepithelial tumor in a 10-year-old girl that showed remarkable radiosensitivity is reported.
  • MRI revealed a brain tumor of mixed intensity with heterogeneous enhancement in the medial temporal lobe, extending to the basal ganglia.
  • The tumor was partially removed.
  • On pathology, the main part of the tumor showed immature features: the tumor cells had a chromatin-rich large nucleus and less cytoplasm, and mitoses and fragmentation of the nuclei were frequent.
  • On immunohistochemistry, the tumor cells were negative for glial fibrillary acidic protein (GFAP) and synaptophysin and positive for Olig2.
  • The part invading into the surrounding brain showed similarities in form to a highly anaplastic astrocytoma.
  • The infiltrating tumor cells were positive for GFAP and less positive for Olig2.
  • After 40 Gy radiation, the residual tumor was markedly reduced.
  • Neuroepithelial tumors rarely show such high radiosensitivity, and the reason for the radiosensitivity in the present case may have been the immaturity of the tumor cells.
  • [MeSH-minor] Astrocytoma. Basic Helix-Loop-Helix Transcription Factors / analysis. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Ki-67 Antigen / analysis. Neoplasm, Residual. Nerve Tissue Proteins / analysis. Radiotherapy Dosage. Synaptophysin / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425048.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / Synaptophysin
  •  go-up   go-down


22. Ritz R, Müller M, Dietz K, Duffner F, Bornemann A, Roser F, Tatagiba M: Hypericin uptake: a prognostic marker for survival in high-grade glioma. J Clin Neurosci; 2008 Jul;15(7):778-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericin uptake: a prognostic marker for survival in high-grade glioma.
  • Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV.
  • In summary, HY uptake by ex vivo glioblastoma cell cultures seems to be positively associated with survival of patients with malignant glioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Drug Resistance, Neoplasm / genetics. Glioma / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / metabolism. Astrocytoma / physiopathology. Cell Line, Tumor. Cell Proliferation. Disease-Free Survival. Drug Therapy. Female. Fluorescence. Glioblastoma / drug therapy. Glioblastoma / metabolism. Glioblastoma / physiopathology. Humans. Light. Lipoproteins, LDL / metabolism. Male. Microscopy, Fluorescence / methods. Middle Aged. Models, Statistical. Predictive Value of Tests. Prognosis. Radiation-Sensitizing Agents / metabolism. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2009 Oct;16(10):1381-2 [19595595.001]
  • (PMID = 18394904.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipoproteins, LDL; 0 / Radiation-Sensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


23. Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V: Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer; 2009;9:372
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
  • BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas.
  • As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the treatment of recurrent WHO grade 3 and 4 astrocytic gliomas in adults.
  • METHODS: 10 patients with advanced recurrent anaplastic astrocytoma (n = 2) or glioblastoma (n = 8) aged 32-62 years were recruited prior to the planned interim analysis of the study.
  • Primary endpoints were the evaluation of toxicities according to the CTCAE v.3.0, and the observation of radiological tumor responses based on MacDonald criteria.
  • One tumor remained stable for 2 months with sulfasalazine treatment, at the lowest daily dose of the drug.
  • Side effects were common, as all patients developed grade 1-3 adverse events (mean: 7.2/patient), four patients developed grade 4 toxicity.
  • CONCLUSION: Although the proper influence of sulfasalazine treatment on patient outcome was difficult to ascertain in these debilitated patients with a large tumor burden (median KPS = 50), ISRCTN45828668 was terminated after its interim analysis.
  • This study urges to exert cautiousness in future trials of Sulfasalazine for the treatment of malignant gliomas.

  • Hazardous Substances Data Bank. SULFASALAZINE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Sep;74(2):105-11 [16193380.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Physiol Rev. 2006 Jan;86(1):279-367 [16371600.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):274-87 [16365179.001]
  • [Cites] BMC Cancer. 2006;6:29 [16448552.001]
  • [Cites] Intern Med. 2006;45(15):927-9 [16946577.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1054-68 [16973133.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):283-90 [17143539.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):79-87 [18095109.001]
  • [Cites] Headache. 2008 Feb;48(2):296-8 [18070060.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):21-30 [18184972.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):593-602 [18181196.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] Clin Neuropharmacol. 2008 Nov-Dec;31(6):368-71 [19050416.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1085-9 [11007945.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Apr;41(4):187-95 [11381677.001]
  • [Cites] J Neurosurg. 2002 May;96(5):909-17 [12005399.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5595-603 [15328202.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neuroimmunol. 1991 Nov;34(2-3):109-20 [1680877.001]
  • [Cites] Neurosci Res. 1992 Feb;13(1):1-17 [1314349.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1759-63 [8105680.001]
  • [Cites] Drugs. 1995 Jul;50(1):137-56 [7588084.001]
  • [Cites] J Clin Invest. 1998 Jan 15;101(2):295-300 [9435300.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1163-74 [9486988.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 9;247(1):79-83 [9636658.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2873-80 [9743348.001]
  • [Cites] Brain Res. 1998 Aug 17;802(1-2):232-40 [9748597.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2261-71 [10327072.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):425-34 [16212807.001]
  • (PMID = 19840379.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN45828668
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3XC8GUZ6CB / Sulfasalazine
  • [Other-IDs] NLM/ PMC2771045
  •  go-up   go-down


24. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol; 2007 May;170(5):1445-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma is the most frequent and most malignant human brain tumor.
  • The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients.
  • In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas.
  • [MeSH-minor] Chromosomes, Human, Pair 10 / genetics. Humans. Loss of Heterozygosity / genetics. Mutation. PTEN Phosphohydrolase / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetics Home Reference. consumer health - chromosome 10.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1993 Jan;52(1):31-8 [8381161.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2736-9 [8504413.001]
  • [Cites] Bioessays. 1993 Oct;15(10):689-90 [7506024.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8113-7 [11719438.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6764-9 [12438278.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1614-7 [9616126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] Oncogene. 1998 Dec 3;17(22):2873-81 [9879993.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):241-5 [10219741.001]
  • [Cites] Genes Dev. 1994 Aug 1;8(15):1739-49 [7958853.001]
  • [Cites] Nat Genet. 1995 Mar;9(3):249-55 [7773287.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2584-92 [7651818.001]
  • [Cites] Glia. 1995 Nov;15(3):308-27 [8586466.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Neurology. 1996 Sep;47(3):684-90 [8797465.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2927-35 [9006938.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Feb;56(2):180-5 [9034372.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Brain Pathol. 1997 Jul;7(3):871-5 [9217972.001]
  • [Cites] J Cell Biol. 1997 Aug 11;138(3):575-88 [9245787.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052-7 [9256433.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5612-9 [9271436.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3672-7 [9288770.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):57-63 [9334810.001]
  • [Cites] Acta Neuropathol. 1997 Oct;94(4):303-9 [9341929.001]
  • [Cites] Genomics. 1997 Dec 1;46(2):291-3 [9417918.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):905-10 [9499454.001]
  • [Cites] Oncogene. 1998 Feb 26;16(8):1009-19 [9519875.001]
  • [Cites] Cell. 1998 Mar 20;92(6):713-23 [9529248.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Mar;57(3):239-45 [9600216.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):115-29 [10903528.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):181-7 [10366450.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7073-83 [16103883.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):108-14 [16404364.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):295-302 [17235514.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Mar;71(3):639-43 [4522778.001]
  • [Cites] Biochem J. 1975 Jun;148(3):521-5 [1200992.001]
  • [Cites] Prog Exp Tumor Res. 1984;27:1-16 [6385121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166-70 [2143581.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Mar;3(2):79-88 [1676908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):80-3 [1614537.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • (PMID = 17456751.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 85
  • [Other-IDs] NLM/ PMC1854940
  •  go-up   go-down


25. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


26. Nano R, Capelli E, Facoetti A, Benericetti E: Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res; 2009 Jul;29(7):2461-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunobiological and experimental aspects of malignant astrocytoma.
  • Starting from 1992, the goal of our studies was to obtain new biological data on malignant astrocytomas to better understand the basic biology of the tumour and these are reviewed here.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596914.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Interleukin-2
  • [Number-of-references] 51
  •  go-up   go-down


27. Paulino AC, Mai WY, Chintagumpala M, Taher A, Teh BS: Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys; 2008 Aug 1;71(5):1381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced malignant gliomas: is there a role for reirradiation?
  • PURPOSE: To review the literature regarding the role of radiotherapy (RT) in the treatment of patients with radiation-induced malignant gliomas (RIMGs).
  • RESULTS: Initial tumor types treated with RT included brain tumor in 37 patients (40%), acute lymphoblastic leukemia in 33 (36%), benign disease in 11 (12%), and other in 11 (12%).
  • Type of RIMG was glioblastoma in 69 (75%) and anaplastic astrocytoma in 23 (25%).
  • One-, 2-, and 5-year overall survival rates were 29.3%, 7.3%, and 0% for patients with glioblastoma and 59.7%, 30.3%, and 20.2% for patients with anaplastic astrocytoma.
  • [MeSH-minor] Astrocytoma / radiotherapy. Glioblastoma / radiotherapy. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Retreatment. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):304-5; author reply 305 [18722290.001]
  • (PMID = 18262733.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


28. Talos IF, Zou KH, Kikinis R, Jolesz FA: Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography. Acad Radiol; 2007 Apr;14(4):431-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography.
  • We hypothesized that white matter infiltration may be common among different types of tumor.
  • MATERIAL AND METHODS: Preoperative, anatomic (T1- and T2-weighted), and LINESCAN diffusion tensor MRI were obtained in 12 patients harboring supratentorial gliomas (World Health Organization [WHO] Grades II and III).
  • A second segmentation and volume measurement was performed on the tumor regions intersecting adjacent white matter fiber tracts.
  • Statistical methods included summary statistics to examine the fraction of tumor volume infiltrating adjacent white matter.
  • RESULTS: There were five patients with low-grade oligodendroglioma (WHO Grade II), one with low-grade mixed oligoastrocytoma (WHO Grade II), one with ganglioglioma, two with low-grade astrocytoma (WHO Grade II), and three with anaplastic astrocytoma (WHO Grade III).
  • We identified white matter tracts infiltrated by tumor in all 12 cases.
  • The median tumor volume (+/- standard deviation) in our patient population was 42.5 +/- 28.9 mL.
  • The median tumor volume (+/- standard deviation) infiltrating white matter fiber tracts was 5.2 +/- 9.9 mL.
  • The median percentage of tumor volume infiltrating white matter fiber tracts was 21.4% +/- 9.7%.
  • However, prospective, large population studies are required to definitively clarify this issue, and how infiltration relates to histologic tumor type, tumor size, and location.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):967-75 [11382961.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):377-80 [11891834.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):93-108 [12044998.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):568-75 [12296640.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1333-42 [12507131.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):358-70; discussion 370-1 [15271242.001]
  • [Cites] Radiology. 2004 Aug;232(2):451-60 [15215555.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):678-84; discussion 684-5 [8692384.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):253-8; discussion 258-9 [8832661.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jul-Aug;21(4):554-66 [9216759.001]
  • [Cites] Brain Res. 1998 Jan 5;780(1):27-33 [9473573.001]
  • [Cites] Med Image Anal. 1996 Mar;1(1):35-51 [9873920.001]
  • [Cites] Clin Neurol Neurosurg. 2005 Apr;107(3):174-80 [15823671.001]
  • [Cites] Radiology. 2005 Aug;236(2):615-20 [16040917.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • [Cites] Radiology. 2006 Apr;239(1):217-22 [16484348.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-292-303; discussion ONS-303-4 [16582653.001]
  • [Cites] Radiology. 2006 May;239(2):506-13 [16641355.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):179-85 [16739029.001]
  • [Cites] Neuroimage. 2006 Sep;32(3):1127-33 [16798013.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 17368212.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013218-098542; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIGMS NIH HHS / GM / R01 GM074068; United States / NCRR NIH HHS / RR / U41 RR019703-03S1; United States / NIBIB NIH HHS / EB / P41 EB015898; United States / NLM NIH HHS / LM / R01 LM007861; United States / NCRR NIH HHS / RR / P41 RR013218-02; United States / NCRR NIH HHS / RR / RR019703-03S1; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCRR NIH HHS / RR / RR013218-108434; United States / NCRR NIH HHS / RR / RR013218-098542; United States / NCI NIH HHS / CA / P01 CA067165; United States / NCRR NIH HHS / RR / P41 RR013218-108434
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS21072; NLM/ PMC2397554
  •  go-up   go-down


29. Pavlisa G, Rados M, Pavlisa G, Pavic L, Potocki K, Mayer D: The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema. Clin Imaging; 2009 Mar-Apr;33(2):96-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The differences of water diffusion between brain tissue infiltrated by tumor and peritumoral vasogenic edema.
  • The differences between peritumoral brain tissue infiltrated by tumor and vasogenic edema were prospectively evaluated by comparing the apparent diffusion coefficient (ADC) of peritumoral areas of infiltrative tumors (anaplastic astrocytomas and glioblastomas) to that of peritumoral areas of noninfiltrative tumors (metastatic carcinomas) on 54 patients.
  • Peritumoral ADCs indicated the possibility of differentiation between tumor infiltration and vasogenic edema, as well as between primary gliomas and metastases.
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / pathology. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19237051.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY: EGFR tyrosine kinase domain mutations in human gliomas. Neurology; 2005 Apr 26;64(8):1444-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas.
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / enzymology. Astrocytoma / genetics. Carcinoma / drug therapy. Carcinoma / enzymology. Carcinoma / genetics. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Genetic Testing. Glioblastoma / drug therapy. Glioblastoma / enzymology. Glioblastoma / genetics. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / enzymology. Oligodendroglioma / genetics. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Structure, Tertiary / genetics. Quinazolines / pharmacology. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851741.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


31. Perez-Saldana MT, Vilar C, Geffner-Sclarsky D, Belenguer-Benavides A, Del Villar-Igea A, Gil-Fortuno M, Bahamonde D: [Meningoencephalomyelitis as the initial symptom of a brain tumour mimicking encephalitis due to herpes simplex virus: a case report]. Rev Neurol; 2007 Mar 16-31;44(6):348-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Meningoencefalomielitis como manifestacion inicial de un tumor cerebral que imita una encefalitis por virus del herpes simple: descripcion de un caso.
  • A tumoural aetiology is rare and they are generally malignant tumours with an ominous prognosis.
  • We report a case of meningoencephalomyelitis that initially presented as encephalitis due to herpes simplex virus (HSV) and which was finally seen to be an anaplastic oligoastrocytoma.
  • The post-mortem examination revealed a grade III oligoastrocytoma in both temporal lobes, which had extended into the adjacent subarachnoid space and the cerebral and cervical leptomeninges.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Encephalitis, Herpes Simplex / etiology. Meninges / pathology. Meningitis / etiology


32. Kim JH, Choi C, Benveniste EN, Kwon D: TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun; 2008 Dec 5;377(1):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells.
  • Matrix metalloproteinase-9 (MMP-9) is an important angiogenic and prognostic factor in malignant tumors.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as the death ligand, which induces preferential apoptosis of transformed tumor cells.
  • We demonstrated that TRAIL induces MMP-9 expression in human astrocytoma cells, which is preceded by activation of extracellular signal-regulated protein kinase (ERK).
  • These findings indicate that TRAIL treatment in human astrocytoma cells leads to the activation of NF-kappaB and subsequent expression of MMP-9, which are dependent on ERK activation.
  • Collectively, these results suggest that TRAIL has alternative biological functions in addition to its role in inducing apoptosis in human malignant astrocytoma cells.
  • [MeSH-major] Astrocytoma / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Matrix Metalloproteinase 9 / biosynthesis. TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Butadienes / pharmacology. Cell Line, Tumor. Enzyme Activation. Humans. NF-kappa B / metabolism. Nitriles / pharmacology. Protein Kinase Inhibitors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834856.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / NF-kappa B; 0 / Nitriles; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / U 0126; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


33. Levin VA, Ictech S, Hess KR: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer; 2007;7:106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.
  • BACKGROUND: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials.
  • CONCLUSION: Based on PFS rates at 6, 9, and 12 months for AG patients, a differential of 1.5 to 2 years is the norm and could invalidate overall survival as an end-point for phase III studies in patients with AG.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Oligodendroglioma / drug therapy. Oligodendroglioma / mortality

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2604-13 [10561328.001]
  • [Cites] Neurology. 1984 May;34(5):615-9 [6538653.001]
  • [Cites] Cancer Treat Rep. 1984 Jul-Aug;68(7-8):969-73 [6744348.001]
  • [Cites] Neurology. 1985 Feb;35(2):219-26 [3969210.001]
  • [Cites] J Neurooncol. 1985;3(1):19-21 [2987424.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):799-806 [3021932.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):464-71 [3029339.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):52-4 [2829615.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):319-23 [3221259.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2420-3 [2555038.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):27-30 [1902506.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1945-9 [1658242.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1432-7 [1380989.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4):715-26 [7611028.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):1983-7 [8616836.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):145-51 [9210061.001]
  • [Cites] Neurology. 1998 Mar;50(3):777-81 [9521274.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):83-90 [16639492.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):981-90 [12631596.001]
  • [Cites] Cancer Res. 1970 Oct;30(10):2451-5 [5474173.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] Cancer. 1975 Jun;35(6):1551-7 [1148989.001]
  • [Cites] Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):327-31 [1149010.001]
  • [Cites] Adv Neurol. 1976;15:315-25 [779423.001]
  • [Cites] J Neurosurg. 1977 Feb;46(2):145-54 [833632.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] J Med Chem. 1980 Jun;23(6):682-4 [7392035.001]
  • [Cites] Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44 [7407756.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • (PMID = 17587447.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1919386
  •  go-up   go-down


34. Galloway M: CD34 expression in glioblastoma and giant cell glioblastoma. Clin Neuropathol; 2010 Mar-Apr;29(2):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study aimed to determine whether CD34 is expressed in glioblastomas and giant cell glioblastomas, as this information may be of value when attempting to differentiate between giant cell glioblastomas and other relevant differential diagnoses such as pleomorphic xanthoastrocytomas with anaplastic features and anaplastic gangliogliomas.
  • CD34 staining in isolation is unlikely to be of assistance in differentiating between giant cell glioblastoma and pleomorphic xanthoastrocytomas with anaplastic features or anaplastic gangliogliomas.
  • [MeSH-major] Antigens, CD34 / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Astrocytoma / pathology. Diagnosis, Differential. Ganglioglioma / pathology. Glioblastoma / metabolism. Glioblastoma / pathology. Humans

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175958.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Parney IF, Goerss SJ, McGee K, Huston J 3rd, Perkins WJ, Meyer FB: Awake craniotomy, electrophysiologic mapping, and tumor resection with high-field intraoperative MRI. World Neurosurg; 2010 May;73(5):547-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Awake craniotomy, electrophysiologic mapping, and tumor resection with high-field intraoperative MRI.
  • After an initial tumor debulking, the scalp flap was loosely approximated, the wound was covered with additional drapes, and the excess surrounding drapes were trimmed.
  • Additional resection was performed, allowing extensive removal of what proved to be an anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Mapping / methods. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Craniotomy / methods. Electroencephalography. Magnetic Resonance Imaging / methods. Surgery, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920940.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Rousselot C, Francois P, Jan M, Bergemer AM: [Report of seven cases of clear-cell meningioma and a literature review]. Ann Pathol; 2010 Apr;30(2):73-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Etude de sept cas de méningiomes à cellules claires et revue de la littérature.
  • Three patients belonged to the same family, probably affected by neurofibromatosis type 2.
  • CONCLUSION: Our study supports the fact that MCC course is less favourable than meningioma WHO grade I, even in the absence of anaplastic area, high mitotic activity, or necrosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Child, Preschool. Diagnostic Errors. Ependymoma / diagnosis. Female. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mucin-1 / analysis. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / pathology. Receptors, Progesterone / analysis. Retrospective Studies. S100 Proteins / analysis. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20451062.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Receptors, Progesterone; 0 / S100 Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


37. Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O, Hernáiz-Driever P, Théallier-Janko A, Zintl F, Längler A, Wolff JE, Csatary LK: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS; 2006 Oct;114(10):731-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.
  • The case of a 12-year-old boy with anaplastic astrocytoma of the left thalamus is reported.
  • Postoperative irradiation and chemotherapy could not repress tumor progression; therefore, treatment was undertaken with an oncolytic virus, MTH-68/H, an attenuated strain of Newcastle disease virus (NDV), and valproic acid (VPA), an antiepileptic drug, which also has antineoplastic properties.
  • This treatment resulted in a far-reaching regression of the thalamic glioma, but 4 months later a new tumor manifestation, an extension of the thalamic tumor, appeared in the wall of the IVth ventricle, which required a second neurosurgical intervention.
  • Under continuous MTH-68/H - VPA administration the thalamic tumor remained under control, but the rhombencephalic one progressed relentlessly and led to the fatal outcome.
  • In the final stage, a third tumor manifestation appeared in the left temporal lobe.
  • The possible reasons for the antagonistic behavior of the three manifestations of the same type of glioma to the initially most successful therapy are discussed.
  • The comparative histological study of the thalamic and rhombencephalic tumor manifestations revealed that MTH-68/H treatment induces, similar to in vitro observations, a massive apoptotic tumor cell decline.
  • In the rhombencephalic tumor, in and around the declining tumor cells, NDV antigen could be demonstrated immunohistochemically, and virus particles have been found in the cytoplasm of tumor cells at electron microscopic investigation.
  • [MeSH-major] Anticonvulsants / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / therapy. Brain Neoplasms / therapy. Valproic Acid / therapeutic use. Viral Vaccines / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004977.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antigens, Viral; 0 / Newcastle disease virus vaccine MTH-68-H; 0 / Viral Vaccines; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


38. Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C: Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet Cytogenet; 2010 Apr 15;198(2):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
  • There are few reports of loss of heterozygosity (LOH) of 1p and 19q in astrocytic tumors, especially glioblastoma multiforme (GBM).
  • We evaluated 1p and 19q (either or both) heterozygosity status in 71 astrocytomas, including 6 pediatric cases: 20 diffuse astrocytomas (DA), 9 anaplastic astrocytomas (AA), and 42 GBM.
  • Thus, 1p and 19q LOH can occur in astrocytic tumors, most commonly in secondary GBMs without morphological correlation with an oligodendroglial histology.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Amplification. Genes, erbB-1. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20362227.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S, Wolter M, Koch A, Yan PS, Endl E, Wiestler OD, Reifenberger G, Pietsch T, Waha A: Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res; 2010 Feb 15;70(4):1689-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Critical tumor suppression pathways in brain tumors have yet to be fully defined.
  • In 83 astrocytic gliomas and 5 glioma cell lines examined, hypermethylation of the MKP-2 promoter was found to occur relatively more frequently in diffuse or anaplastic astrocytomas and secondary glioblastomas relative to primary glioblastomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. DNA Methylation. Down-Regulation / physiology. Female. Gene Expression Regulation, Neoplastic / physiology. Gene Silencing / physiology. Genes, Tumor Suppressor / physiology. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124482.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP4 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases
  •  go-up   go-down


40. Smith SF, Simpson JM, Sekhon LH: What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? J Clin Neurosci; 2005 Nov;12(8):915-20; discussion 921
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades?
  • OBJECTIVE: To determine changes since 1977 in demographic characteristics, tumour frequencies, surgical management, morbidity and survival for 1,339 patients discharged with astrocytoma (A) and oligodendroglioma (O), which comprise the majority of primary brain cancers, recorded prospectively in northern Sydney neurosurgery databases.
  • Of 144 re-biopsies, 16% had less anaplastic pathology, 54% the same and 30% more anaplastic pathology than the first biopsy.
  • Age and histopathologic grade were predictors of survival from 1980.
  • After adjustment for age using proportional hazards regression, survival improved only for anaplastic A, with a 60% improvement for patients diagnosed in era 3, and a 50% improvement for patients diagnosed in era 4 relative to those in era 1.
  • CONCLUSIONS: Although markers of inpatient care have improved since the 1980s, age-adjusted survival has not increased except for patients with anaplastic A.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neurosurgical Procedures / statistics & numerical data. Oligodendroglioma / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326271.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


41. García-Navarro V, Tena-Suck ML, Celis MA, Vega R, Rembao D, Salinas C: Anaplastic astrocytoma post radiotherapy of pineal germinoma. Arq Neuropsiquiatr; 2009 Sep;67(3A):707-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma post radiotherapy of pineal germinoma.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Neoplasms, Radiation-Induced. Neoplasms, Second Primary / etiology. Pineal Gland


42. Jang FF, Wei W, De WM: Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma. J Ayub Med Coll Abbottabad; 2008 Apr-Jun;20(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
  • BACKGROUND: Astrocytoma is the most malignant intracranial neoplasm and is characterized by high neovascularization and peritumoural brain oedema.
  • METHODS: The expression of two angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor were investigated using immunohistochemistry for astrocytoma from 82 patients and 11 normal human tissues.
  • RESULTS: The expression of vascular endothelial growth factor and basic fibroblast growth factor positively correlate with the pathological grade of astrocytoma, microvessel density numbers and brain oedema, which may be responsible for the increased tumour neovascularization and peritumoural brain oedema.
  • CONCLUSION: The results support the idea that inhibiting vascular endothelial growth factor and basic fibroblast growth factor are useful for the treatment of human astrocytoma and to improve patient's clinical outcomes and prognosis.
  • [MeSH-major] Astrocytoma / blood supply. Brain Edema / etiology. Brain Neoplasms / blood supply. Fibroblast Growth Factor 2 / biosynthesis. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385471.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


43. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer; 2005;5:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.
  • BACKGROUND: Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma.
  • METHODS: Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT.
  • RESULTS: The median overall survival (OS) was 9.3 (1.9-77.6+) months from the time of HFSRT, 15.4 months for grade III and 7.9 months for grade IV tumors (p = 0.029, log-rank test).
  • Median time to tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Disease Progression. Dose-Response Relationship, Radiation. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Neoplasm Recurrence, Local. Nimustine / pharmacology. Prognosis. Recurrence. Stereotaxic Techniques. Teniposide / pharmacology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):155-9 [10776976.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2678-86 [14669289.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Bull Cancer. 2004 Nov;91(11):883-9 [15582893.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):53-7 [10624854.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):226-9 [9167741.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):83-8 [9364636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • (PMID = 15924621.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine; 957E6438QA / Teniposide
  • [Other-IDs] NLM/ PMC1156875
  •  go-up   go-down


44. Gil-Benso R, Lopez-Gines C, Benito R, López-Guerrero JA, Callaghan RC, Pellín A, Roldán P, Cerdá-Nicolas M: Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol; 2007 Sep-Oct;26(5):224-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A genetic alteration that is significantly more frequent in primary than in secondary glioblastomas, the latter arising from preceding low-grade gliomas, is epidermal growth factor receptor gene (EGFR) amplification, whereas TP-53 mutations are significantly more frequent in low-grade gliomas and secondary glioblastomas derived there- from.
  • We report the histological and genetic study of two glioblastomas, one case arising de novo and the other case arising 3 years after a previously diagnosed anaplastic astrocytoma, with concurrent EGFR amplification and TP-53 mutation.
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation


45. Serrano J, Rayo JI, Infante JR, Domínguez L, García-Bernardo L, Durán C, Fernández Portales I, Cabezudo JM: Radioguided surgery in brain tumors with thallium-201. Clin Nucl Med; 2008 Dec;33(12):838-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Malignant astrocytomas show thallium uptake with a high target-to-background ratio, allowing the use of radioguided surgery.
  • METHOD: We report on 6 patients (3 men) diagnosed with malignant astrocytoma.
  • With the gamma probe we confirmed the tumor uptake, and a biopsy sample was taken.
  • After conventional tumor resection, we scanned the surgical bed with the gamma probe.
  • RESULTS: In all patients the biopsy confirmed a high-grade astrocytoma.
  • In all cases we found residual uptake in the surgical bed that was confirmed as residual tumor by pathologic examination.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033782.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


46. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol; 2008 Jun;88(2):121-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade gliomas release excitotoxic concentrations of glutamate which contributes to their malignant phenotype.
  • To improve our understanding of the mechanisms by which glutamate enhances tumor growth and invasion, we examined alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-mediated signaling in glioma cell lines. shRNA was used to stably knockdown GluR1, the most abundant AMPA receptor subunit in glioma, to evaluate its role in tumor signaling, proliferation and tumorigenicity.
  • In a tissue array, there was a statistically significant increase in GluR1 expression in glioblastoma samples compared to anaplastic astrocytoma and low-grade tumors.
  • These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth.
  • [MeSH-minor] Animals. Carcinogenicity Tests. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Down-Regulation / drug effects. Down-Regulation / genetics. Humans. Ki-67 Antigen / metabolism. Mice. Mice, Nude. Microarray Analysis / methods. RNA, Double-Stranded / pharmacology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] Nucleic Acids Res. 2003 Nov 1;31(21):e127 [14576327.001]
  • [Cites] Pharmacol Rev. 1999 Mar;51(1):7-61 [10049997.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):595-614 [14599084.001]
  • [Cites] J Neurosci. 1993 Sep;13(9):3904-15 [8103555.001]
  • [Cites] Neuron. 2000 Jun;26(3):603-17 [10896157.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:601-32 [1667084.001]
  • [Cites] Neuron. 1994 Jun;12 (6):1207-21 [8011335.001]
  • [Cites] J Biol Chem. 1994 Mar 4;269(9):7030-5 [8120067.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • [Cites] Trends Neurosci. 2003 Oct;26(10):543-9 [14522147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7058-61 [11416187.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7987-8001 [17652589.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):163-7 [16144086.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Aug;27(8):1431-43 [17245419.001]
  • [Cites] J Biol Chem. 1993 Feb 15;268(5):3715-9 [8429046.001]
  • [Cites] Neuron. 1999 Mar;22(3):511-24 [10197531.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2279-91 [7557381.001]
  • [Cites] J Med Chem. 1998 Jul 2;41(14):2513-23 [9651156.001]
  • [Cites] J Neurochem. 2003 Mar;84(6):1288-95 [12614329.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):584-7 [9859994.001]
  • [Cites] Nature. 1999 Jan 7;397(6714):72-6 [9892356.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 15;64(8):1195-200 [12234599.001]
  • [Cites] J Neurosci Res. 1998 Dec 15;54(6):814-9 [9856865.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 [11331750.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] J Neurosci. 2005 Feb 16;25(7):1654-63 [15716401.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1934-40 [15753393.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4383-91 [10485487.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Apr;18(4):396-406 [9538905.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):771-81 [15378037.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22783-7 [7559406.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1110-22 [15022276.001]
  • (PMID = 18317690.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Double-Stranded; 0 / RNA, Small Interfering; 0 / Receptors, AMPA; 0 / glutamate receptor ionotropic, AMPA 1
  •  go-up   go-down


47. Xiang C, Sarid R, Cazacu S, Finniss S, Lee HK, Ziv-Av A, Mikkelsen T, Brodie C: Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. Biochem Biophys Res Commun; 2007 Oct 26;362(3):612-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, RTVP-1 and RTVP-1b showed similar patterns of expression in astrocytic tumors; highly expressed in glioblastomas as compared to normal brains, low-grade astrocytomas and anaplastic oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Alternative Splicing. Amino Acid Sequence. Base Sequence. Cell Line, Tumor. Cell Movement. Cell Proliferation. Cloning, Molecular. Humans. Molecular Sequence Data. Protein Isoforms. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825796.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-R21-96965; United States / NCI NIH HHS / CA / R24 CA095809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


48. Argyriou AA, Giannopoulou E, Kalofonos HP: Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology; 2009;77(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
  • Angiogenesis is considered to be a regulating factor of vascular development and growth for malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytomas.
  • The VEGF/VEGFR-2 is the predominant angiogenic signalling pathway in malignant gliomas.
  • Our aim is to review current knowledge on angiogenesis as a molecular pathogenetic mechanism of malignant gliomas and to critically look at and discuss antiangiogenic molecularly targeted therapies for these brain malignancies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19439998.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Number-of-references] 98
  •  go-up   go-down


49. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y: Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol; 2005 Mar;109(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DcR3 has been demonstrated to produce a secreted member of the tumor necrosis factor receptor superfamily that negatively regulates Fas-mediated apoptosis.
  • In this study we examined DcR3 gene amplification, DcR3 mRNA expression, and DcR3 protein expression in 46 human astrocytic brain tumors by quantitative genomic PCR, quantitative reverse transcription-PCR, and immunohistochemistry, respectively.
  • The DcR3 gene amplification was detected in none of 6 (0%) low-grade astrocytomas, 1 of 16 (6%) anaplastic astrocytomas, and 6 of 24 ( 25%) glioblastomas.
  • We thus concluded that high DcR3 mRNA expression and protein expression may be positively related to the gene amplification in astrocytic brain tumors, especially glioblastomas.
  • Further, we speculated that the DcR3 gene amplification with overexpression may be responsible for malignant features in glioblastomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptors, Tumor Necrosis Factor. Receptors, Tumor Necrosis Factor, Member 6b. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627206.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


50. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther; 2007 Jul;6(7):1909-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons learned in the development of targeted therapy for malignant gliomas.
  • The prognosis of patients with glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma remains poor despite standard treatment with radiotherapy and temozolomide.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620423.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  • [Number-of-references] 78
  •  go-up   go-down


51. Bozinov O, Kalk JM, Krayenbühl N, Woernle CM, Sure U, Bertalanffy H: Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas. Neurol Med Chir (Tokyo); 2010;50(8):617-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
  • This gene is highly expressed in various types of human tumors including malignant gliomas.
  • The expression level of IL-13Ralpha2 was examined in a total of 45 tissue samples of anaplastic astrocytomas (AAs) World Health Organization (WHO) grade III, glioblastomas (GBMs) WHO grade IV, and first-recurrent glioblastomas (frGBMs) after treatment with radiation and chemotherapy.
  • The expression level of IL-13Ralpha2 (15 fold) was significantly reduced in frGBMs compared to the primary GBMs (p = 0.014), and significantly reduced by more than 15 fold (p = 0.003) in all untreated malignant astrocytomas (AAs and GBMs) compared with treated frGBMs.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805641.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Actins; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0S726V972K / Nimustine; 63231-63-0 / RNA; 957E6438QA / Teniposide
  •  go-up   go-down


52. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Pavon LF, Marti LC, Sibov TT, Malheiros SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E, Gamarra LF: The ultrastructural study of tumorigenic cells using nanobiomarkers. Cancer Biother Radiopharm; 2010 Jun;25(3):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances, patients with malignant brain tumors still have a poor prognosis.
  • Glioblastoma (WHO grade 4 astrocytoma), the most malignant brain tumor, represents 50% of all astrocytomas, with a median survival rate of <1 year.
  • The process of tumor cell labeling using nanoparticles can successfully contribute to the identification of tumorigenic cells and consequently for better understanding of glioblastoma genesis and recurrence.
  • In addition, this method may help further studies in tumor imaging, diagnosis, and prognostic markers detection.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, CD29 / immunology. Antigens, CD29 / metabolism. Antigens, CD44 / immunology. Antigens, CD44 / metabolism. Biomarkers / analysis. Biomarkers / chemistry. Cell Line, Tumor. Cell Membrane / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Cytoplasmic Vesicles / metabolism. Endocytosis / immunology. Flow Cytometry. Forkhead Transcription Factors / chemistry. Forkhead Transcription Factors / metabolism. Glycoproteins / immunology. Glycoproteins / metabolism. Humans. Immunophenotyping. Magnetite Nanoparticles / chemistry. Microscopy, Electron, Transmission. Nanomedicine / methods. Peptides / immunology. Peptides / metabolism. Quantum Dots. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578834.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD29; 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44 protein, human; 0 / ENG protein, human; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Glycoproteins; 0 / Magnetite Nanoparticles; 0 / Peptides; 0 / Receptors, Cell Surface
  •  go-up   go-down


54. Arjona D, Bello MJ, Alonso ME, Aminoso C, Isla A, De Campos JM, Sarasa JL, Gutierrez M, Villalobo A, Rey JA: Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol; 2005 Aug;31(4):384-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
  • This report investigates the presence of mutations, amplification and/or over-expression of the EGFR gene in 86 glial tumours including 44 glioblastomas, 21 anaplastic astrocytomas, and 21 WHO grade II astrocytomas, using polymerase chain reaction/single-strand conformation polymorphism, semiquantitative reverse-transcription-polymerase chain reaction (RT-PCR) and Southern Blot techniques.
  • These findings corroborate that EGFR is non-randomly involved in malignant glioma development and that different mutant forms participate in aberrant activation of tyrosine kinase pathways.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Epidermal Growth Factor / genetics. Gene Amplification


55. Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A: Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res; 2008 Apr;30(3):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.
  • It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood.
  • The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
  • METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation).
  • Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls.
  • Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / cerebrospinal fluid. Interleukin-10 / blood. Interleukin-10 / cerebrospinal fluid. Transforming Growth Factor beta2 / blood. Transforming Growth Factor beta2 / cerebrospinal fluid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848206.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta2; 130068-27-8 / Interleukin-10
  •  go-up   go-down


56. Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y: Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun; 2008 Sep 19;374(2):394-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Podocalyxin expression in malignant astrocytic tumors.
  • Recently, we revealed that highly sulfated KS or another mucin-like transmembrane sialoglycoprotein podoplanin/aggrus is upregulated in malignant astrocytic tumors.
  • The aim of this study is to examine the relationship between podocalyxin expression and malignant progression of astrocytic tumors.
  • In this study, 51 astrocytic tumors were investigated for podocalyxin expression using immunohistochemistry, Western blot analysis, and quantitative real-time PCR.
  • Immunohistochemistry detected podocalyxin on the surface of tumor cells in six of 14 anaplastic astrocytomas (42.9%) and in 17 of 31 glioblastomas (54.8%), especially around proliferating endothelial cells.
  • In diffuse astrocytoma, podocalyxin expression was observed only in vascular endothelial cells.
  • Podocalyxin might be associated with the malignant progression of astrocytic tumors, and be a useful prognostic marker for astrocytic tumors.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / pathology. Sialoglycoproteins / analysis
  • [MeSH-minor] Blotting, Western. Humans. Immunohistochemistry. Polymerase Chain Reaction. Prognosis. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639524.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / podocalyxin
  •  go-up   go-down


57. Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL: Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer; 2008 Mar 1;112(5):1139-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
  • BACKGROUND: The prognosis for patients with recurrent high-grade gliomas is poor and treatment options are limited.
  • METHODS: This multi-institutional trial enrolled 120 patients with recurrent glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), or anaplastic oligodendroglioma (AO).
  • Grade 3/4 toxicities included neutropenia (1.1%), thrombocytopenia (3.6%), and anemia (0.3%) (graded according to the World Health Organization grading system).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


58. Rathi KR, Radotra BD, Khosla VK: Proliferative index in astrocytic tumours. Indian J Pathol Microbiol; 2007 Oct;50(4):754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative index in astrocytic tumours.
  • The accurate grading of astrocytic tumours is of prime importance because it is critical to the patient management and survival/outcome.
  • Although internationally accepted WHO grading system of CNS tumours is based on histological features of H&E stained sections, yet there are cases where differentiation between grade II and grade III is difficult particularly when the biopsy is small.
  • Formalin-fixed paraffin-embedded surgical specimens from 90 cases of astrocytic tumours, 30 each of low-grade astrocytoma (grade II), anaplastic astrocytoma (grade III), and glioblastoma multiforme (grade IV), were immunostained by standard indirect immunoperoxidase technique using MIB-1 monoclonal antibody.
  • The mean MIB-1 LI values of astrocytomas, anaplastic astrocytomas and glioblastomas were 1.75 +/- 1.5%, 8.74 +/- 6.2%, and 20.54 +/- 12.2% respectively and there was statistically significant difference between grade II and III (Unpaired "t" test, T value 5.907, p value < 0.001) and grade III and grade IV (T value 4.734, p value < 0.001).
  • The statistical analysis also revealed that the mean MIB-1 LI increased with histological grade of malignancy (One way ANOVA test, p value < 0.001).
  • This investigation further reinforces and corroborates the findings that MIB-1 LI is useful tool in assigning grading to the astrocytic tumours and hence in treatment modalities and should be used routinely.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / pathology. Cell Proliferation. Glioblastoma / classification. Glioblastoma / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306542.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


59. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E: MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer; 2009 Sep 15;125(6):1407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
  • Although the oncogenic and tumor suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating tumor invasion and migration remains largely unexplored.
  • Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines.
  • The expression levels of miR-10b were associated with higher grade glioma.
  • In addition, mRNA expressions of RhoC and urokinase-type plasminogen activator receptor (uPAR), which were thought to be regulated by miR-10b via HOXD10, were statistically significantly correlated with the expression of miR-10b (p < 0.001, p = 0.001, respectively).
  • Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02).
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19536818.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


60. Oake C, Borg MF, Hanieh A, Byard RW: Childhood glioblastoma multiforme of the spinal cord. Australas Radiol; 2006 Aug;50(4):360-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytoma accounts for more than 50% of all central nervous system tumours diagnosed, with particular prevalence in the 15- to 34-year-old age bracket, rarely arising in younger children.
  • In 1995, a 7-year-old boy presented in Emergency with a 3-day history of severe radicular back pain and associated muscle spasms, exacerbated by lying on his back.
  • Both bone scan and plain X-rays were unremarkable; however, MRI showed a 3-cm space-occupying lesion at the level of T5-T6.
  • The patient proceeded to biopsy and partial excision of the tumour through laminectomy, histology confirming an anaplastic astrocytoma (glioblastoma multiforme), St Anne Mayo grade 4.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884424.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


61. Ehling R, Sterlacci W, Maier H, Berger T: A 45-year old male with left-sided hemihypesthesia. Brain Pathol; 2010 Mar;20(2):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extensive immunological and radiological investigations were not able to differentiate between an intrinsic brain tumor and a demyelinating disease.
  • Stereotactic biopsies of the brainstem were performed; the findings of abundant Rosenthal fibers, interjacent spindle-shaped and gemistocytic cells partially with dark and irregularly formed nuclei favored primarily the diagnosis of a malignant astrocytoma, although a demyelinating disease could not be definitely excluded.

  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438473.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Vidiri A, Carapella CM, Pace A, Mirri A, Fabi A, Carosi M, Giannarelli D, Pompili A, Jandolo B, Occhipinti E, Di Giovanni S, Crecco M: Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. J Exp Clin Cancer Res; 2006 Jun;25(2):177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas.
  • Forty-seven patients with Glioblastoma (42) and Anaplastic Astrocytoma (5) were studied with MR 24 hrs after surgery.
  • In order to evaluate the role of early MR in defining the extent of surgical resection and its relation with the prognosis of malignant glioma patients, three categories of surgical resection were considered: gross total, sub-total and partial resection.
  • The study confirms that early-MR has to be considered an accurate technique for monitoring the extension of malignant glioma surgical resection and shows a good correlation between early-MR findings, PFS and ST.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918127.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Comincini S, Ferrara V, Arias A, Malovini A, Azzalin A, Ferretti L, Benericetti E, Cardarelli M, Gerosa M, Passarin MG, Turazzi S, Bellazzi R: Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy. Oncol Rep; 2007 May;17(5):989-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy.
  • Recently, ectopic expression of doppel was found in two different tumor types, specifically in glial and haematological cancers.
  • In order to address clinical important issues, PRND mRNA expression was investigated in a panel of 111 astrocytoma tissue samples, histologically classified according to the World Health Organization (WHO) criteria (6 grade I pilocytic astrocytomas, 15 grade II low-grade astrocytomas, 26 grade III anaplastic astrocytomas and 64 grade IV glioblastoma multiforme).
  • Real-time PRND gene expression profiling, after normalisation with GAPDH, revealed large differences between low (WHO I and II) and high grade (III and IV) of malignancy (P<0.001).
  • Extensive differences in PRND gene expression were also found within each grade of malignancy, suggesting that PRND mRNA quantitation might be useful to distinguish astrocytoma subtypes, and important in disease stratification and in the assessment of specific treatment strategies.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Prions / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390034.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / PRND protein, human; 0 / Prions
  •  go-up   go-down


64. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL: Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res; 2005 Jul 1;65(13):5535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
  • As we have found that Lyn, but not Fyn, activity promotes migration of glioblastoma cells in response to the cooperative signal generated by platelet-derived growth factor receptor beta and integrin alpha(v)beta3, we compared the activity and expression of Lyn and Fyn in glioblastoma (grade IV) tumor biopsy samples with that in anaplastic astrocytoma (grade III) tumors, nonneoplastic brain, and normal autopsy brain samples.
  • Lyn kinase activity was significantly elevated in glioblastoma tumor samples.
  • The levels of phosphorylation of the autophosphorylation site were consistent with significantly higher Lyn activity in glioblastoma tumor tissue than nonneoplastic brain.
  • Immunostaining revealed that Lyn is located primarily in the glioblastoma cells in the tumor biopsies.
  • These data indicate that Lyn kinase activity is significantly elevated in glioblastoma tumors and suggest that it is the Lyn activity that promotes the malignant phenotype in these tumors.
  • [MeSH-minor] Astrocytoma / enzymology. Astrocytoma / genetics. Astrocytoma / pathology. Biopsy. Brain / enzymology. Endothelial Cells / enzymology. Humans. Immunohistochemistry. Phosphotransferases / genetics. Phosphotransferases / metabolism. Protein-Tyrosine Kinases. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-fyn. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994925.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97110; United States / NCI NIH HHS / CA / P50 CA97247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / CSK tyrosine-protein kinase; EC 2.7.10.2 / FYN protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fyn; EC 2.7.10.2 / lyn protein-tyrosine kinase; EC 2.7.10.2 / src-Family Kinases
  •  go-up   go-down


65. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Mahasittiwat P, Mizoe JE, Hasegawa A, Ishikawa H, Yoshikawa K, Mizuno H, Yanagi T, Takagi R, Pattaranutaporn P, Tsujii H: l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):515-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy.
  • METHODS AND MATERIALS: This retrospective study analyzed 16 patients with malignant glioma (4 patients, anaplastic astrocytoma; 12 patients, glioblastoma multiforme) treated with surgery and carbon ion radiotherapy from April 2002 to Nov 2005.
  • The MET-PET target volume was compared with gross tumor volume and CTV, defined by using computed tomography/magnetic resonance imaging (MRI).
  • CONCLUSIONS: For patients with malignant gliomas, MET-PET has a possibility to be a predictor of outcome in carbon ion radiotherapy.
  • [MeSH-major] Astrocytoma / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioblastoma / radionuclide imaging. Methionine. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiotherapy Planning, Computer-Assisted / methods. Retrospective Studies. Tomography, X-Ray Computed / methods. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17900820.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


67. Bentsion DL, Gvozdev PB, Sakovich VP, Fialko NV, Kolotvinov VS, Baiankina SN: [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2006 Jan-Mar;(1):18-21; discussion 21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histostructural distribution was as follows: low-grade astrocytoma (grade II according to the WHO classification) in 2 patients, anaplastic astrocytoma (AA) in 3, glioblastoma multiforme (GBM) in 5.
  • Five patients had solid tumor deposits in the brain.
  • After having histological findings, plastic intrastats whose number had been determined by the volume of a target were implanted into a tumor by the predetermined path.
  • All patients with low-grade astrocytoma and one patient with anaplastic astrocytoma were alive at month 24 after treatment termination.
  • The mean lifespan of patients with malignant gliomas and solid tumor metastasis was 11.5 and 5.8 months, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739930.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


68. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res; 2005 Jan 1;11(1):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
  • PURPOSE: The activator protein (AP)-2alpha transcription factor plays a crucial role in the progression of several human tumors, including malignant melanoma, prostate, and breast cancer.
  • Anderson Cancer Center since 1986 to include 72 glioblastomas, 49 anaplastic astrocytomas, 9 low-grade astrocytoma, 37 oligodendrogliomas, 37 anaplastic oligodendrogliomas, 15 mixed oligoastrocytomas, 20 anaplastic mixed oligoastrocytomas, and 7 gliosarcomas.
  • RESULTS: AP-2alpha expression was lost on 99% (P < 0.001) and 98% (P < 0.001) of glioblastomas and anaplastic astrocytomas, respectively, compared with grade 2 astrocytomas and normal brain, all of which (100%) maintained expression of AP-2alpha.
  • However, there was no significant effect of loss of AP-2alpha expression on survival observed after adjustment for patient age, Karnofsky Performance Scale score, tumor grade, and extent of resection (rate ratio, 1.2; 95% confidence interval, 0.6-2.2; P = 0.6).
  • CONCLUSIONS: AP-2alpha expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity, possibly through subsequent deregulation of target genes.
  • Of all the previously characterized markers of progression, the loss of AP-2alpha would be the most common (96.2%) molecular marker as an astrocytic tumor evolves from grade 2 to 3.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Motifs. Antigens, CD / biosynthesis. Antigens, CD146. Astrocytoma / metabolism. Brain / metabolism. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p21. Disease Progression. Humans. Immunohistochemistry. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Neural Cell Adhesion Molecules / biosynthesis. Oligodendroglioma / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-kit / biosynthesis. Time Factors. Transcription Factor AP-2. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / T-32-09666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / MCAM protein, human; 0 / Neural Cell Adhesion Molecules; 0 / TFAP2A protein, human; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


69. Pan JW, Zhan RY, Tong Y, Zhou YQ, Zhang M: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B; 2005 Jul;6(7):693-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
  • OBJECTIVE: To investigate the relationship between the expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF) and angiogenesis in primary astrocytoma.
  • METHODS: Thirty-seven primary astrocytomas and 4 astrocytic hyperplasia samples were collected and divided into three groups according to histological grade.
  • The intensity of immunoreactivity was graded according to the percentage of positive tumor cells.
  • RESULTS: No eNOS and VEGF were expressed in the astrocytes and vascular endothelium in astrocytic hyperplasia.
  • The expression of eNOS or VEGF was light in low-grade astrocytoma and strong in glioblastoma. eNOS expression in astrocytoma was very positively correlated with VEGF. eNOS and VEGF expression in anaplastic astrocytoma was median in contrast to the low grade astrocytoma and glioblastoma.
  • Lower microvascular density was found in low grade astrocytoma than that in higher grade malignant ones.
  • The expressions of eNOS and VEGF were correlated with microvascular density and tumor malignancy.
  • CONCLUSION: This finding suggests that eNOS and VEGF may have cooperative effect in tumor angiogenesis and play an important role in the pathogenesis of primary astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):189-97 [10607702.001]
  • [Cites] Cardiovasc Res. 1999 Mar;41(3):773-80 [10435050.001]
  • [Cites] Circ Res. 2000 Apr 28;86(8):892-6 [10785512.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Jun;22(3):267-74 [10872046.001]
  • [Cites] Br J Neurosurg. 2000 Dec;14(6):543-8 [11272032.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):568-81 [11166270.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9 [11226286.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):139-48 [11245273.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):607-11 [11267968.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L278-90 [11404271.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1433-41 [11516104.001]
  • [Cites] Ann Anat. 2003 Dec;185(6):549-54 [14704000.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2567-78 [9616228.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):597-601 [10376602.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):24-8; discussion 29 [10414562.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):299-304 [10769671.001]
  • (PMID = 15973775.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1389807
  •  go-up   go-down


70. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, Srividya MR, Vrinda M, Sridevi S, Shailaja BC, Samuel C, Prasanna KV, Thennarasu K, Balasubramaniam A, Chandramouli BA, Hegde AS, Somasundaram K, Kondaiah P, Rao MR: Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev; 2010 Jun;19(6):1399-408
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
  • In view of this, we evaluated the expression of IGFBP isoforms (IGFBP-2, -3, and -5) during malignant progression of astrocytoma and their prognostic significance in glioblastoma.
  • METHODS: The expression of IGFBP isoforms was analyzed in diffusely infiltrating astrocytomas by real-time quantitative PCR (n = 203) and immunohistochemistry (n = 256).
  • Statistical methods were used to assess their grade-specific expression pattern and mRNA-protein intercorrelation.
  • RESULTS: The mean transcript levels of IGFBP-2 and -3 were significantly higher in glioblastomas (GBM) relative to anaplastic astrocytoma (AA), diffuse astrocytoma (DA), and controls whereas IGFBP-5 mRNA was higher in GBM relative to AA and controls (P < 0.05).
  • CONCLUSIONS: This study shows the associations of IGFBP-2, -3, and -5 expression with increasing grades of malignancy in astrocytomas.
  • IMPACT: IGFBP isoforms have emerged as biomarkers with diagnostic and prognostic utility in astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / biosynthesis. Insulin-Like Growth Factor Binding Protein 5 / biosynthesis. Insulin-Like Growth Factor Binding Proteins / biosynthesis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20501753.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IGFBP3 protein, human; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Protein 5; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger
  •  go-up   go-down


71. Stark AM, Modlich S, Claviez A, van Baalen A, Hugo HH, Mehdorn HM: Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report. J Neurooncol; 2007 Sep;84(3):325-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report.
  • [MeSH-major] Astrocytoma / congenital. Astrocytoma / secondary. Brain Neoplasms / congenital. Brain Neoplasms / pathology. Ependymoma / secondary. Meningeal Neoplasms / secondary


72. Kaderali Z, Lamberti-Pasculli M, Rutka JT: The changing epidemiology of paediatric brain tumours: a review from the Hospital for Sick Children. Childs Nerv Syst; 2009 Jul;25(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We classified 1,866 surgical pathology cases of brain tumours in children under the age of 19 according to the World Health Organization 2007 consensus and analysed them by gender, histological tumour type, age distribution and decade.
  • The main histological tumour types were low-grade (I/II) astrocytomas (26.4%), medulloblastoma (10.6%), anaplastic astrocytoma/glioblastoma multiforme (7.1%) and ependymoma (7.0%).
  • Over three decades, an increasing proportion of certain tumour types, including pilocytic astrocytoma, atypical teratoma/rhabdoid tumours and neuronal/mixed neuronal-glial tumours was seen.
  • [MeSH-minor] Age Factors. Astrocytoma / epidemiology. Astrocytoma / pathology. Canada / epidemiology. Child. Ependymoma / epidemiology. Ependymoma / pathology. Glioblastoma / epidemiology. Glioblastoma / pathology. Humans. Medulloblastoma / epidemiology. Medulloblastoma / pathology. Neoplasm Staging. Neoplasms, Complex and Mixed / epidemiology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Nerve Tissue / epidemiology. Neoplasms, Nerve Tissue / pathology. Rhabdoid Tumor / epidemiology. Rhabdoid Tumor / pathology. Risk Factors. Sex Factors. Teratoma / epidemiology. Teratoma / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Paediatr Perinat Epidemiol. 1996 Jul;10(3):319-38 [8822774.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118-31 [15313584.001]
  • [Cites] Cancer. 1999 May 1;85(9):2077-90 [10223251.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1871-2 [8230273.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2809-15 [16380987.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):88-91 [12672035.001]
  • [Cites] Childs Nerv Syst. 2005 Nov;21(11):940-4 [16044344.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1492-3 [10717635.001]
  • [Cites] Childs Nerv Syst. 1991 Jun;7(3):150-3 [1878869.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 7;85(13):1024-5 [8515483.001]
  • [Cites] Acta Neurochir (Wien). 1993;123(1-2):14-24 [8213273.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1594-6 [2213900.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Nov;25(11):842-4 [14608192.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:177-84 [8549470.001]
  • (PMID = 19082611.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


73. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A; 2007 Jul 10;104(28):11736-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies show that IGFBP2 coexpression results in progression to a higher-grade glioma in platelet-derived growth factor beta (PDGFB)-driven tumors.
  • These anaplastic oligodendrogliomas are characterized by increased cellularity, vascular proliferation, small regions of necrosis, increased mitotic activity, and increased activation of the Akt pathway.
  • Combined expression of IGFBP2 or Akt with K-Ras was required to form astrocytomas, indicating that activation of two separate pathways is necessary for gliomagenesis.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Eur J Pediatr. 1996 Feb;155(2):81-6 [8775218.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2308-13 [9215312.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1218-23 [9448312.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]
  • [Cites] Eur Urol. 2005 May;47(5):695-702 [15826765.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3022-7 [15687344.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):356-68 [15967113.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):397-406 [15967117.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):657-64 [16699322.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14085-91 [16569642.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7429-37 [16885338.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Growth Horm IGF Res. 2006 Aug;16(4):224-39 [16893667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3414-9 [17360660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5563-8 [17372210.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6289-96 [17438529.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:101-27 [11008486.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7100-13 [12370832.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):824-54 [12466191.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1796-806 [15014034.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):859-68 [15171717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1031-5 [7682560.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] Int J Cancer. 1994 May 15;57(4):491-7 [7514152.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • (PMID = 17606927.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098503; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA- 16672; United States / NCI NIH HHS / CA / R01 CA98503; United States / NIDDK NIH HHS / DK / 5 T90 DK070109-02; United States / NIDDK NIH HHS / DK / T90 DK070109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC1913900
  •  go-up   go-down


74. Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P: Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci; 2005 May;12(4):389-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of high grade glioma - long term survival.
  • For primary (newly diagnosed) tumours, median survival from initial diagnosis was 76.5 months for anaplastic astrocytoma (AA) and 14.3 months for glioblastoma multiforme (GBM).

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925768.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Hematoporphyrins
  •  go-up   go-down


75. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M: Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain; 2007 Dec;130(Pt 12):3336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients.
  • To evaluate whether the serum concentration of glial fibrillary acidic protein (GFAP) may indicate glioblastoma multiforme (GBM) in patients with single supratentorial space-occupying lesions, we prospectively examined 50 consecutive patients with histologically proven GBM, World Health Organization (WHO) grade IV, 14 patients with anaplastic astrocytoma (WHO grade III), 4 patients with anaplastic oligodendroglioma, 13 patients with diffuse astrocytoma (WHO grade II), 17 patients with a single cerebral metastasis and 50 healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / diagnosis. Glial Fibrillary Acidic Protein / blood. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Necrosis. Neoplasm Proteins / blood. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998256.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins
  •  go-up   go-down


76. Roselli F, Pisciotta NM, Aniello MS, Niccoli-Asabella A, Defazio G, Livrea P, Rubini G: Brain F-18 Fluorocholine PET/CT for the assessment of optic pathway glioma in neurofibromatosis-1. Clin Nucl Med; 2010 Oct;35(10):838-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging, magnetic resonance spectroscopy (MRS), and F-18 fluorocholine revealed a splenial mass with imaging features compatible with malignant astrocytoma.


77. Panigrahy A, Nelson MD Jr, Finlay JL, Sposto R, Krieger MD, Gilles FH, Blüml S: Metabolism of diffuse intrinsic brainstem gliomas in children. Neuro Oncol; 2008 Feb;10(1):32-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to compare the metabolic profile of DIBSGs with that of astrocytomas elsewhere in the CNS and to determine whether the measurement of metabolic features can improve the assessment of disease status.
  • Control data for baseline studies of DIBSGs were obtained from 14 untreated regular and anaplastic astrocytomas.
  • At baseline, creatine and total choline (tCho) were significantly lower in DIBSGs than in astrocytomas elsewhere in the CNS (4.3 +/- 1.1 vs. 7.5 +/- 1.9 mmol/kg, p < 0.001; 1.9 +/- 0.7 vs. 4.2 +/- 2.6, p < 0.001).
  • Subsequent metabolic changes that have been associated with malignant degeneration preceded clinical deterioration.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Oct;87(4):525-34 [9322843.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):22-9 [15690498.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] NMR Biomed. 2000 Jan;13(1):28-36 [10668051.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Neuroradiology. 2000 May;42(5):333-8 [10872152.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] NMR Biomed. 2000 Nov;13(7):398-406 [11114063.001]
  • [Cites] Anat Rec. 2001 Apr15;265(2):54-84 [11323770.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1316-24 [11498420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31 [15850898.001]
  • [Cites] Radiology. 2005 Sep;236(3):1020-5 [16118174.001]
  • [Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):560-72 [16551993.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):806-9 [16611768.001]
  • [Cites] Radiology. 2006 Aug;240(2):318-32 [16864664.001]
  • [Cites] Pediatr Neurol. 2002 May;26(5):374-8 [12057798.001]
  • [Cites] Magn Reson Med. 2002 Sep;48(3):555-8 [12210925.001]
  • [Cites] Magn Reson Med. 2002 Dec;48(6):949-58 [12465103.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] No Shinkei Geka. 2003 Feb;31(2):167-72 [12616652.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):375-82; discussion 382 [12968803.001]
  • [Cites] Magn Reson Imaging. 2003 Oct;21(8):923-8 [14599543.001]
  • [Cites] NMR Biomed. 2004 Feb;17(1):10-20 [15011246.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(2):73-83 [2132928.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):303-24 [1333263.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Radiology. 1994 Apr;191(1):279-82 [8134588.001]
  • [Cites] NMR Biomed. 1994 May;7(3):149-55 [8080717.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1827-34 [8082086.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Magn Reson Med. 1996 Sep;36(3):335-9 [8875401.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):407-14 [9012466.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] Can J Neurol Sci. 1998 Feb;25(1):13-22 [9532276.001]
  • [Cites] Childs Nerv Syst. 1998 Apr-May;14(4-5):167-73 [9660117.001]
  • [Cites] Neuroimaging Clin N Am. 1998 Nov;8(4):781-807 [9769342.001]
  • [Cites] Magn Reson Imaging. 1998 Nov;16(9):1093-106 [9839993.001]
  • [Cites] Neuropediatrics. 1998 Dec;29(6):328-30 [10029356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1861-8 [10213493.001]
  • [Cites] Magn Reson Med. 1999 Oct;42(4):643-54 [10502752.001]
  • [Cites] Bull Cancer. 2004 Jun;91(6):E167-83 [15562562.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8220-8 [15623597.001]
  • [Cites] Magn Reson Med. 1998 Jan;39(1):53-60 [9438437.001]
  • (PMID = 18003889.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / U01 CA97452-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2600836
  •  go-up   go-down


78. Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Ishii S, Takahashi JA, Kato K: Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci; 2009 Jan;100(1):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique.
  • The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and oligodendroglial tumors that were more reliable than the traditional histological classification scheme.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038000.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A, Korkolopoulou P: Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol; 2009 Jun;70(6):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.
  • Malignant astrocytomas are highly vascular neoplasms with potent angiogenic activity.
  • The present study aimed to investigate peripheral and local expression of interleukin (IL)-8 in astrocytomas with possible associations to IL-6, cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) expression, and microvessel morphometry.
  • IL-6- and IL-8-secreting peripheral blood monocytes (PBMCs) were evaluated in 17 glioblastoma (WHO grade IV), 5 anaplastic astrocytoma (WHO grade III), and 6 diffuse astrocytoma patients (WHO grade II), in parallel with 23 healthy controls using enzyme-linked immunosorbent spot (ELISPOT) assay.
  • The IL-8 expression was assessed immunohistochemically in patients' tumor tissue sections and correlated with the expression of COX-2, VEGF, IL-6, and microvessel morphometry (assessed using CD34 antibody).
  • IL-8 immunoreactivity was detected in malignant cells or macrophages in perivascular areas and in pseudopalisading cells around necrosis and was positively correlated with histological grade (p = 0.0175) and tumor necrosis (p = 0.0793).
  • The coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways.
  • Moreover, our study seems to be the first attempt to link IL-8 expression by tumor cells with histological grade, implicating its potent role in gliomagenesis.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Cyclooxygenase 2 / immunology. Microvessels / immunology. Vascular Endothelial Growth Factor A / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332096.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interleukin-6; 0 / Interleukin-8; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


80. Kawarabuki K, Ohta T, Hashimoto N, Wada K, Maruno M, Yamaki T, Ueda S: Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol; 2005 Mar-Apr;24(2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present case, tumor lesions were observed in each cerebellar hemisphere.
  • The left-side lesion was diagnosed as glioblastoma, and the right-side lesion as malignant astrocytoma by histopathology.
  • Immunohistochemistry revealed that the tumor cells of the left-side lesion was positive for p53, whereas epidermal growth factor receptors (EGFR) were negative in tumor cells from both sides.
  • Genetic alterations were investigated using a genome DNA microarray (GenoSensor Array 300), which has led us to define this tumor as a secondary glioblastoma.


81. Choi K, Ryu SW, Song S, Choi H, Kang SW, Choi C: Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ; 2010 May;17(5):833-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis.
  • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family of cytokines, causes apoptosis by caspase activation in various cell types, particularly in transformed cells.
  • We report here a new signal transduction pathway involving protein kinase Cdelta (PKCdelta), NADPH oxidase 4 (NOX4) and reactive oxygen species (ROS), that inhibits caspase-dependent cell death induced by TRAIL ligation in human malignant astrocytoma cells.
  • [MeSH-major] Apoptosis / physiology. Astrocytoma / metabolism. Caspase 3 / metabolism. Reactive Oxygen Species / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Humans. Immunoblotting. NADPH Oxidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876066.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.6.3.- / NOX4 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


82. Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA: Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed; 2007 Dec;20(8):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 145 histologically diagnosed brain tumour spectra were acquired [14 astrocytoma grade II (AS2), 15 astrocytoma grade III (AS3), 42 glioblastoma (GBM), 41 metastases (MET) and 33 meningioma (MNG)], and linear discriminant analyses (LDA) were performed on the LCModel analysis of the spectra and the original spectra.
  • LDA of AS2, MNG and high-grade tumours (HG, comprising GBM and MET) correctly classified 94% using the LCModel dataset compared with 93% using the spectral dataset.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326043.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Hiremath GK, Bingaman WE, Prayson RA, Nair D: Oligoastrocytoma presenting with intractable epilepsy. Epileptic Disord; 2007 Sep;9(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Oligoastrocytomas (OA) are mixed gliomas with distinct oligodendroglial and astrocytic neoplastic components.
  • Surgical pathology revealed low-grade OA (WHO II) in five patients, and anaplastic OA in one.
  • There were no surgical complications, clinical or radiographic tumor recurrence at a mean follow up period of 3.2 years (range 2-8).
  • CONCLUSION: As a result of our small sample size, general conclusions may be imprecise, but this review suggests that OA behave similar to other tumors related to intractable epilepsy: they usually have a preoperative seizure course of many years, an excellent rate of seizure-freedom following surgery, and are in general, low-grade tumors with an indolent course for which serial imaging is sufficient follow-up.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Epilepsy / drug therapy. Epilepsy / etiology
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Craniotomy. Drug Resistance. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Memory / physiology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884756.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


84. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brännström T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol; 2006 Jul;78(3):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
  • Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma.
  • The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV.
  • For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
  • In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
  • Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
  • In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
  • Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
  • In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Estramustine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1713-6 [2697186.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):360-6 [8832674.001]
  • [Cites] Br J Cancer. 1988 Sep;58(3):326-9 [3052561.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Prostate. 1989;14(1):27-43 [2648345.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):693-6 [2369085.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):215-20 [15072470.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1111-7 [11181676.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):962-4 [1709687.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):358-61 [8431366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):142-8 [10389990.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1254-9 [10715295.001]
  • [Cites] J Neurooncol. 1994;22(2):111-26 [7745464.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):717-20 [7710934.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):87-91 [9516956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):555-7 [8005815.001]
  • [Cites] Clin Pharmacokinet. 1998 Feb;34(2):163-72 [9515186.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1415-7 [8137240.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):422-30; discussion 430-1 [8384327.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2079-84 [9748122.001]
  • [Cites] J Neurooncol. 1995;23(3):191-200 [7673981.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4974-9 [8069865.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • (PMID = 16598426.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35LT29625A / Estramustine
  •  go-up   go-down


85. Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C: A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):993-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
  • PURPOSE: To determine the maximum tolerated dose (MTD) of fractionated stereotactic radiosurgery (SRS) with gefitinib in patients with recurrent malignant gliomas.
  • Eligible patients had pathologically proved recurrent anaplastic astrocytoma or glioblastoma.
  • Dose-limiting toxicity (DLT) was any Grade 3 toxicity.
  • Grade 1-2 gefitinib-related dermatitis and diarrhea were common (10 and 7 patients, respectively).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Neoplasm Recurrence, Local / therapy. Quinazolines / therapeutic use. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / surgery. Astrocytoma / therapy. Dose Fractionation. Female. Humans. Male. Maximum Tolerated Dose. Mental Status Schedule. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17967517.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


86. Jeong SM, Chung YG, Lee JB, Shin IY: Intracranial dissemination from spinal cord anaplastic astrocytoma. J Korean Neurosurg Soc; 2010 Jan;47(1):68-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dissemination from spinal cord anaplastic astrocytoma.
  • We report a case of intracranial dissemination developing approximately 4 months after partial removal of a spinal cord anplastic astrocytoma in a 22-year-old male.
  • The tumor was partially removed.
  • The final histologic diagnosis was anaplastic astrocytoma.
  • He underwent computed tomography-guided stereotactic biopsy and histological appearance was consistent with anaplastic astrocytoma.
  • The clinical course indicates that the tumor originated in the spinal cord and extended into the subarachnoid space, first the spinal canal and later intracranial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathology. 2006 Dec;26(6):519-27 [17203587.001]
  • [Cites] Pathol Oncol Res. 2006;12(3):143-7 [16998593.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):211-6 [16552620.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 May;32(5):281-4 [1378944.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):39-41 [11546571.001]
  • [Cites] Rinsho Hoshasen. 1989 Feb;34(2):249-52 [2754823.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):295-300 [3392575.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • (PMID = 20157383.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2817520
  • [Keywords] NOTNLM ; Anaplastic astrocytoma / Intracranial dissemination / Spinal cord
  •  go-up   go-down


87. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar Ø, Kumar T, Haakonsen M, Langberg CW, Nakstad PH: Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol; 2010 Apr;51(3):316-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
  • BACKGROUND: Brain metastases and primary high-grade gliomas, including glioblastomas multiforme (GBM) and anaplastic astrocytomas (AA), may be indistinguishable by conventional magnetic resonance (MR) imaging.
  • PURPOSE: To assess the value of MR spectroscopy (MRS) using short and intermediate echo time (TE) in differentiating solitary brain metastases and high-grade gliomas on the basis of differences in metabolite ratios in the intratumoral and peritumoral region.
  • MATERIAL AND METHODS: We performed MR imaging and MRS in 73 patients with histologically verified intraaxial brain tumors: 53 patients with high-grade gliomas (34 GBM and 19 AA) and 20 patients with metastatic brain tumors.
  • The differences in the metabolite ratios between high-grade gliomas/GBM/AA and metastases were analyzed statistically.
  • Cutoff values of Cho/Cr, Cho/NAA, and NAA/Cr ratios in the peritumoral edema, as well as Cho/Cr and NAA/Cr ratios in the tumoral core for distinguishing high-grade gliomas/GBM/AA from metastases were determined by receiver operating characteristic (ROC) curve analysis.
  • RESULTS: Significant differences were noted in the peritumoral Cho/Cr, Cho/NAA, and NAA/ Cr ratios between high-grade gliomas/GBM/AA and metastases.
  • ROC analysis demonstrated a cutoff value of 1.24 for peritumoral Cho/Cr ratio to provide sensitivity, specificity, positive (PPV), and negative predictive values (NPV) of 100%, 88.9%, 80.0%, and 100%, respectively, for discrimination between high-grade gliomas and metastases.
  • CONCLUSION: The results of this study demonstrate that MRS can differentiate high-grade gliomas from metastases, especially with peritumoral measurements, supporting the hypothesis that MRS can detect infiltration of tumor cells in the peritumoral edema.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Radiol. 2010 Apr;51(3):326-8 [20192894.001]
  • (PMID = 20092374.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Contrast Media; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; K2I13DR72L / Gadolinium DTPA; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


88. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K: Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol; 2007 Apr;82(2):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.
  • OBJECTIVE: Subcellularly localized (nuclear and/or cytoplasmic) survivin has various functions, and correlates with prognosis of malignant tumors.
  • However, there have been no reports about the significance of subcellularly localized survivin in high-grade astrocytomas.
  • The aim of the present study was to examine the relationship between prognosis and subcellular localization of survivin in high-grade astrocytoma.
  • METHODS: We immunohistochemically examined the pattern of subcellular localization of survivin expression (nuclear, cytoplasmic, or both) in 51 patients with high-grade astrocytoma (19 anaplastic astrocytomas; 32 glioblastomas).
  • We statistically examined the relationship between survivin localization and prognosis, using multivariate analysis including other clinicopathological factors (age, sex, WHO grade, extent of resection, MIB-1 labeling index, and expression of p53 and epidermal growth factor receptor).
  • CONCLUSIONS: We found that simultaneous expression of survivin in both the nucleus and cytoplasm is an important prognostic factor for high-grade astrocytoma.
  • The present findings indicate that subcellular localization of survivin expression is a reliable prognostic factor for patients with this tumor.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Subcellular Fractions. Survival Rate. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):401-7 [15241527.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):151-6 [15925995.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):44-53 [11925104.001]
  • [Cites] Eur J Surg Oncol. 2003 May;29(4):379-82 [12711293.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3531-4 [15867343.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2723-34 [15735764.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):115-9 [12556969.001]
  • [Cites] Cancer Lett. 2001 Feb 10;163(1):109-16 [11163114.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Cell Death Differ. 2002 Dec;9(12):1334-42 [12478470.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):501-10 [14742256.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Acta Oncol. 2003;42(5-6):582-8 [14596516.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):212-6 [15611788.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):108-14 [16404364.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii27-9 [16760287.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1378-85 [15195112.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1077-83 [12671708.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Mol Cancer. 2005 Mar 02;4(1):11 [15743529.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):509-12 [15578717.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1654-60 [15520067.001]
  • (PMID = 17151933.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / epidermal growth factor receptor-neu receptor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


89. Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y: Clinical results of BNCT for malignant brain tumors in children. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results of BNCT for malignant brain tumors in children.
  • It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue.
  • However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells.
  • We evaluated the clinical results and courses in patients with malignant glioma under 15 years.
  • There were 3 glioblastomas (GBM), 6 anaplastic astrocytomas(AAS), 7 primitive neuroectodermal tumors (PNET), 6 pontine gliomas and 1 anaplastic ependymoma.
  • All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth.
  • All pontine glioma patients died due to regrowth of the tumor.
  • Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence.
  • BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation.
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Ependymoma / pathology. Ependymoma / radiotherapy. Fatal Outcome. Female. Glioblastoma / pathology. Glioblastoma / radiotherapy. Humans. Infant. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406652.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


90. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR: Glioma pathophysiology: insights emerging from proteomics. Brain Pathol; 2010 Jul;20(4):691-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas account for >50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common.
  • The protein network discovered (containing TP53 and RB1 at its core) compliments recent findings in genomic studies of malignant glioma.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Proteomics


91. Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J: Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo); 2007 Aug;47(8):341-9; discussion 350
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
  • Promoter methylation of the deoxyribonucleic acid (DNA) repair gene, O(6)-methylguanine-DNA methyltransferase (MGMT), is associated with improved outcome of patients with glioblastoma multiforme and anaplastic astrocytoma treated with temozolomide (TMZ).
  • Molecular genetic analysis of loss of heterozygosity (LOH) of 1p, 19q, or 10q, p53 mutation, and MGMT promoter methylation was performed in 44 assessable tumor specimens obtained from 46 patients with recurrent malignant gliomas, including 21 with glioblastoma multiforme, 17 with anaplastic astrocytoma, and eight with anaplastic oligoastrocytoma, which have heterogeneous features and variable histological diagnosis, to assess the correlation with the response to TMZ.
  • LOH of 1p in the heterogeneous population of malignant gliomas may be one of the important factors besides MGMT methylation that predict better outcome in patients treated with TMZ.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm / genetics. Glioma / genetics. Mutation / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents, Alkylating / pharmacology. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. DNA Mutational Analysis. DNA Repair / genetics. Female. Genetic Markers / genetics. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Loss of Heterozygosity / genetics. Male. Middle Aged. Promoter Regions, Genetic / genetics. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721049.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


92. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T: Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg; 2010 Aug;113(2):358-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response.
  • METHODS: The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma.
  • Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1alpha (HIF-1alpha) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery.
  • RESULTS: The FRP-170 PET images showed marked uptake with upregulation of HIF-1alpha in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors.
  • This new method can assess tumor hypoxia preoperatively and noninvasively.
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Biopsy. Carbon Isotopes. Cell Division. Female. Fluorodeoxyglucose F18. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Methionine. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Protons. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895196.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / FRP-170; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 0 / Protons; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


93. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


94. Gelpi E, Popovic M, Preusser M, Budka H, Hainfellner J: Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis. Neuropathology; 2005 Sep;25(3):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: implications for differential diagnosis.
  • Pleomorphic xanthoastrocytoma (PXA) is an uncommon, usually low-grade, astrocytic tumor.
  • Characteristic histological features include tumor cell pleomorphism and lipidization of tumor cells.
  • In these cases, the differential diagnosis needs to exclude other malignancies, for example, glioblastoma or malignant fibrous histiocytoma.
  • A 43-year-old woman was operated on for a left occipital parasagital tumor attached to the dura.
  • Histopathology showed a pleomorphic tumor with moderate mitotic activity and necrosis, lack of GFAP immunoreactivity and ultrastructural detection of premelanosome-like structures.
  • Three years later she had local tumor recurrence and underwent another operation.
  • The recurrent tumor showed similar plain histology as the first specimen.
  • In contrast, anti-GFAP immunoreactivity was now detectable in pleomorphic tumor cells.
  • Focal GFAP staining of tumor cells was now achieved.
  • We conclude that non-standard GFAP staining protocols may enhance sensitivity and thus lead to detection of a low level of GFAP expression in tumor specimens, in which PXA is considered in the differential diagnosis.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / metabolism
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Melanoma / pathology. Microscopy, Confocal. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193842.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


95. Nagatani M, Ando R, Yamakawa S, Saito T, Tamura K: Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis. Toxicol Pathol; 2009 Aug;37(5):599-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical studies on spontaneous rat astrocytomas and malignant reticulosis.
  • Among spontaneous neoplasms of the rat central nervous system, the discrimination between astrocytoma and malignant reticulosis (MR) is sometimes difficult because of their similar cell morphology and infiltration patterns.
  • These cases were diagnosed as benign/malignant astrocytoma containing no neoplastic oligodendroglial elements or MR according to the diagnostic criteria of the World Health Organization International Classification of Rodent Tumors (Mohr et al. 1994).
  • Astrocytomas were divided into three types and MR into two types based on the number of lesions, cellularity and infiltration patterns, and so on.
  • None of the tumor types showed any reactivity for GFAP or S-100 protein.
  • From the results of morphological and immunohistochemical examinations, it was indicated that there are no distinctive differences between spontaneous astrocytomas and MR in rats, and they are probably derived from the same cell lineage, that is, microglia, macrophage, or radial glia.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Central Nervous System Neoplasms / metabolism. Central Nervous System Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487256.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Vimentin
  •  go-up   go-down


96. Shibahara I, Kanamori M, Kumabe T, Endo H, Sonoda Y, Ogawa Y, Watanabe M, Tominaga T: Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma. Brain Tumor Pathol; 2009;26(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma.
  • The incidence of hemorrhagic onset in pilocytic astrocytoma and pilomyxoid astrocytoma, and the clinical and histological characteristics, were compared to other types of neuroepithelial tumors or nonhemorrhagic pilocytic astrocytoma by retrospective review of 445 consecutive neuroepithelial tumors treated at our institute.
  • Hemorrhagic onset was observed in 4 of 35 (11.4%) patients with pilocytic astrocytoma and pilomyxoid astrocytoma, with higher incidence than in glioblastoma (3.9%), anaplastic oligodendroglioma (7.7%), and anaplastic ependymoma (7.1%).
  • The hemorrhagic onset occurred in 2 patients with sporadic pilocytic astrocytoma, 1 with pilocytic astrocytoma associated with neurofibromatosis type 1, and 1 with pilomyxoid astrocytoma.
  • There was no correlation between hemorrhagic onset and clinical features, including age, sex, tumor location, proliferative activity, or microvascular proliferation.
  • Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma is not as uncommon as was previously thought, so pilocytic astrocytoma or pilomyxoid astrocytoma should be considered in the differential diagnosis of patients with brain tumors manifesting as hemorrhagic onset.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / pathology


97. Jin S, Sun C, Yu S, Wang Q, Wu W, Sun Y, Zhao W, An T: Chromosome DNA imbalances in human astrocytic tumors: a comparative genomic hybridization study of 63 Chinese patients. Pathol Res Pract; 2010 Oct 15;206(10):674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome DNA imbalances in human astrocytic tumors: a comparative genomic hybridization study of 63 Chinese patients.
  • Astrocytic tumors are the most frequent primary brain neoplasms.
  • Analysis of chromosome DNA imbalance may help to advance diagnosis, grading, and classification, and to determine appropriate therapeutic approaches for tumors of astrocytic lineages.
  • Comparative genomic hybridization (CGH) provides comprehensive information about chromosome DNA aberrations, and is an important technique for evaluating the differences at genomic levels among the same or different grade tumors.
  • In this study, 63 astrocytic tumors of Chinese patients were screened by CGH, and the relationship between their chromosome DNA imbalances and the histopathological classification, grading, and clinical features was analyzed.
  • The losses of 4q and 10q correlated with age in the group of anaplastic astrocytoma, which was unreported in the literature.
  • Our data was the first report on the chromosomal aberrations of astrocytic tumors of Chinese patients.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. China. Female. Gene Expression Regulation, Neoplastic. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Phenotype. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20591577.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


98. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, Sato A, Yamada T, Takahashi S: Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology; 2006 Dec;241(3):839-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis.
  • PURPOSE: To retrospectively assess the apparent diffusion coefficient (ADC) for prediction of malignancy and prognosis of malignant astrocytic tumors.
  • Findings from 37 consecutive patients (21 men, 16 women; mean age, 43 years) with pathologically proved malignant astrocytic tumors that included 22 glioblastomas (GBMs) and 15 anaplastic astrocytomas (AAs) were retrospectively evaluated.
  • The minimum ADC value of each tumor was preoperatively determined from several regions of interest defined in the tumor, preferably with avoidance of cystic or necrotic components, on ADC maps derived from isotropic diffusion-weighted images.
  • CONCLUSION: The minimum ADC of malignant astrocytomas can provide additional information about their clinical malignancy related to posttreatment prognosis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Image Processing, Computer-Assisted. Ki-67 Antigen / analysis. Male. Predictive Value of Tests. Prognosis. ROC Curve. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 17032910.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


99. Webster M, Cairncross G, Gertler S, Perry J, Wainman N, Eisenhauer E: Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group. Invest New Drugs; 2005 Dec;23(6):591-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
  • PURPOSE: A multi-centre phase II study of SarCNU-a novel chloroethylnitrosourea (CNU)-in patients with recurrent malignant glioma to assess response rate, survival and effects of treatment.
  • PATIENTS AND METHODS: Ten patients with histologically proven malignant glioma (seven with glioblastoma multiforme (GBM) and three with anaplastic astrocytoma) received SarCNU (860 mg/m(2)) orally on days 1, 5 and 9 on a 6 week schedule.
  • Of eight evaluable patients, five demonstrated at least one grade deterioration in DLCO from baseline.
  • CONCLUSION: Despite promising preclinical data, SarCNU caused pulmonary toxicity in patients with recurrent malignant glioma and we plan no further studies in this indication.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Carmustine / analogs & derivatives. Central Nervous System Neoplasms / drug therapy. Glioblastoma / drug therapy. Lung / drug effects
  • [MeSH-minor] Academies and Institutes. Adult. Aged. Canada. Carbon Monoxide / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pulmonary Diffusing Capacity / drug effects

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. Carbon monoxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Mol Pharmacol. 1993 Jul;44(1):204-9 [8341272.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):232-40 [12525514.001]
  • [Cites] Oncology (Williston Park). 1998 Apr;12(4):537-43, 547; discussion 547-8, 553 [9575527.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Pharmacol Ther. 1989;41(3):443-60 [2654964.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Cancer Res. 1977 Apr;37(4):1022-7 [557367.001]
  • [Cites] Cancer Treat Rep. 1976 Nov;60(11):1691-4 [1021241.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3895-8 [9307267.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 16034522.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7U1EE4V452 / Carbon Monoxide; BHB013S3MO / 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide; U68WG3173Y / Carmustine
  •  go-up   go-down


100. Dresemann G: Temozolomide in malignant glioma. Onco Targets Ther; 2010;3:139-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in malignant glioma.
  • Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and the most frequent primary tumor of the central nervous system.
  • Primary resection that is as complete as possible is recommended for malignant glioma.
  • For temozolomide naive GBM and astrocytoma grade III patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies.
  • The role of lower dosed, dose-dense, or continuous regimen with or without drug combination and the role of temozolomide for newly diagnosed astrocytoma grade III and low grade glioma still has to be determined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856849.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2939767
  • [Keywords] NOTNLM ; astrocytoma WHO grade III / glioblastoma multiforme / malignant glioma / temozolomide
  •  go-up   go-down






Advertisement